[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 105
1. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • Two thirds of the total samples of every compared pair as training set were used to set up discriminating patterns, and one third of total samples of every compared pair as test set were used to cross-validate; simultaneously, discriminate-cluster analysis derived SPSS 10.0 software was used to compare Astrocytoma grade I-II with grade III-IV ones.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • Total accuracy of 85.7%, accuracy of grade I-II Astrocytoma was 86.7%, accuracy of III-IV Astrocytoma was 84.6% were obtained when grade I-II Astrocytoma was compared with grade III-IV ones (discriminant analysis).
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


2. Palani M, Arunkumar R, Janardhanam VA: Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients. Ann Neurosci; 2010 Jul;17(3):120-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients.
  • BACKGROUND: Glioma, a neoplasm of neuroglial cells, is the most common type of brain tumor, constituting more than 50% of all brain tumors.
  • PURPOSE: This report summarizes the current knowledge regarding the clinical utility of biochemical enzyme markers for both diagnostic and therapeutic purposes in different grades of glioma.
  • METHODS: Sixty patients with different grades of glioma include glioblastoma multiforme (n=20), Anaplastic astrocytoma (n=10).
  • Ependymoma (n=10), Pilocytic astrocytoma (n=10) and patients with benign lesions (n=5) served as controls.
  • CK, Na-K(+) ATPases, 5'-Nucleotidases showed marked increase in grade IV.
  • Similarly, Mg2-ATPase, Ca2+ATPases showed significant increase in grade III.
  • CONCLUSION: The clinical importance for classification and treatment of glioma is governed by biochemical enzyme markers.
  • The study of enzymes supported by related chromosomal changes is anticipated to provide better appreciation of biological properties in different grades of glioma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25205887.001).
  • [ISSN] 0972-7531
  • [Journal-full-title] Annals of neurosciences
  • [ISO-abbreviation] Ann Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4116979
  • [Keywords] NOTNLM ; Antioxidants / Biochemical profile in glioma / Chromosomal aberrations / Enzymes / Glioma
  •  go-up   go-down


3. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT: Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res; 2009 Aug;29(8):3269-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of CD68 and kallikrein 6 in human glioma.
  • AIMS: To evaluate the expression of CD68 and kallikrein 6 in human gliomas, and investigate their prognostic significance for survival of brain cancer patients in comparison to some known prognostic markers.
  • PATIENTS AND METHODS: Histological sections of 51 primary astrocytic tumours (11 benign, 40 malignant) were immunohistochemically stained for CD68, cathepsin B, kallikrein 6 and Ki-67.
  • CD68 and kallikrein 6 expressions were also analyzed by real-time PCR in nine brain tumour biopsies.
  • High CD68 and cathepsin B staining scores were significantly, more frequent in the malignant than in the benign tumours (p=0.036 and p=0.014, respectively).
  • In contrast, the benign group presented a stronger immunoreactivity for kallikrein 6 compared with the malignant tumours (p=0.013).
  • A CD68 staining score of tumour cells higher than 3 was a significant predictor of shorter overall survival (p<0.01) in all patients and of borderline significance in the malignant group (p=0.057).
  • CONCLUSION: Kallikrein 6 was down-regulated in malignant glioma, but this differential expression did not have an impact on patient prognosis.
  • In contrast, immunostaining of glioma tissue for CD68 and for cathepsin B may be used for prognosis of survival in these patients.
  • This finding suggests that besides the known role of cathepsin B in invasion and angiogenesis, CD68 may be also associated with glioma progression.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Kallikreins / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661345.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


Advertisement
4. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.
  • Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves.
  • These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


5. Nikitin KV, Shishkina LV, Pronin IN, Il'ialov SR, Kostiuchenko VV, Golanov AV: [Radiation necrosis after stereotactic radiosurgery for benign glioma]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Jul-Sep;(3):37-42; discussion 42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation necrosis after stereotactic radiosurgery for benign glioma].
  • In spite of low invasiveness this method produces risk of development of radiation-induced complications including symptomatic focal necrosis.
  • Authors report a case of radiation-induced necrosis occurred in a patient treated for benign glioma using Leksell Gamma-Knife.
  • Morphological features, risk factors, incidence, differential diagnosis and treatment of cerebral radiation-induced necroses are briefly discussed in this article.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Gamma Rays / adverse effects. Glioma / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy / adverse effects. Radiotherapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088448.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


6. Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH: Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res; 2008 Dec 15;68(24):10358-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
  • Neurofibromatosis-1 (NF1) is a common tumor predisposition syndrome in which affected individuals develop benign and malignant tumors.
  • Previous studies from our laboratory and others have shown that benign tumor formation in Nf1 genetically engineered mice (GEM) requires a permissive tumor microenvironment.
  • In the central nervous system, Nf1 loss in glia is insufficient for glioma formation unless coupled with Nf1 heterozygosity in the brain.
  • Our subsequent studies identified Nf1+/- microglia as a critical cellular determinant of optic glioma growth in Nf1 GEM.
  • Using NF1 as an experimental paradigm to further characterize the role of microglia in glioma growth, we first examined the properties of Nf1+/- microglia in vitro and in vivo.
  • Moreover, SP600125 treatment of Nf1 optic glioma-bearing GEM results in reduced optic glioma proliferation in vivo.
  • Collectively, these findings suggest that Nf1+/- microglia represent a good model system to study the role of specialized microglia in brain tumorigenesis and identify a unique Nf1 deregulated pathway for therapeutic studies aimed at abrogating microenvironmental signals that promote brain tumor growth.
  • [MeSH-major] MAP Kinase Kinase 4 / metabolism. Microglia / enzymology. Neurofibromatosis 1 / enzymology. Optic Nerve Glioma / enzymology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074905.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA84314
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Cytokines; 0 / Neurofibromin 1; 0 / Neuropeptides; 0 / RNA, Messenger; 0 / Rac1 protein, mouse; 0 / anthra(1,9-cd)pyrazol-6(2H)-one; EC 2.7.12.2 / MAP Kinase Kinase 4; EC 3.6.5.2 / rac GTP-Binding Proteins; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


7. Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res; 2005 Apr 1;65(7):2565-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
  • The presence of common genomic deletions in the 19q13 chromosomal region in neuroblastomas and gliomas strongly suggests the presence of a putative tumor suppressor gene for these neoplasms in this region that, despite much effort, has not yet been identified.
  • In an attempt to address this issue, we compared the expression profile of 89 neuroblastoma tumors with that of benign ganglioneuromas by microarray analysis.
  • We found that EMP3 undergoes hypermethylation-mediated transcriptional silencing in neuroblastoma and glioma cancer cell lines, whereas the use of the demethylating agent 5-aza-2-deoxycytidine restores EMP3 gene expression.
  • Furthermore, the reintroduction of EMP3 into neuroblastoma cell lines displaying methylation-dependent silencing of EMP3 induces tumor suppressor-like features, such as reduced colony formation density and tumor growth in nude mouse xenograft models.
  • Screening a large collection of human primary neuroblastomas (n = 116) and gliomas (n = 41), we observed that EMP3 CpG island hypermethylation was present in 24% and 39% of these tumor types, respectively.
  • Thus, EMP3 is a good candidate for being the long-sought tumor suppressor gene located at 19q13 in gliomas and neuroblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Silencing. Genes, Tumor Suppressor. Glioma / genetics. Membrane Glycoproteins / genetics. Neuroblastoma / genetics


8. Zhou Y, Liu F, Xu Q, Wang X: Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy. J Exp Clin Cancer Res; 2010;29:138
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy.
  • BACKGROUND: Gliomas represent the most common primary malignant brain tumors, yet little is known about the molecular pathogenesis of these tumors.
  • The aim of this study was to examine the expression profile of DKK-1 gene in human glioma and its association with tumor malignancy.
  • METHODS: We determined the expression levels of DKK-1 transcript and protein in 12 glioblastoma cell lines, medulloblastoma cells, low-grade glioma cells, and human astrocyte cells by semiquantitative RT-PCR and ELISA.
  • A total of 47 tumor biopsy specimens and 11 normal brain tissue samples from patients with cerebral trauma internal decompression were embedded in paraffin blocks and used for immunostaining.
  • Twenty-six primary tumors and 7 corresponding brain samples were stored in liquid nitrogen and used for RT-PCR.
  • We further examined serologic concentrations and cerebral fluid levels of DKK-1 in patients with tumors.
  • RESULTS: DKK-1 could only be detected in 12 human glioblastoma cell lines, not in a panel of other tumor and normal cell lines.
  • The difference between glioma patients and healthy individuals was significant.
  • Kendall's tau-c association analysis also revealed the increased DKK-1 protein expression in tumor tissues of higher pathologic classification.
  • The levels of cerebral fluid DKK-1 protein were significantly higher in glioma patients than in healthy donors or in neuronal benign tumor patients, suggesting that the DKK-1 molecule in cerebral fluids can be applicable to detect the presence of glioma and be developed as a novel prognostic treatment.
  • CONCLUSION: The Wnt antagonist DKK-1 gene may have important roles in glioma tumorigenesis and act as a novel biomarker in human malignant glioblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Gene Expression Profiling. Glioma / genetics. Intercellular Signaling Peptides and Proteins / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 1999 Oct 1;238(2):301-13 [10570958.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2517-25 [17363569.001]
  • [Cites] Cytogenet Cell Genet. 2000;89(3-4):220-4 [10965128.001]
  • [Cites] Curr Biol. 2000 Dec 14-28;10(24):1611-4 [11137016.001]
  • [Cites] Nature. 2001 May 17;411(6835):321-5 [11357136.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):683-6 [11433302.001]
  • [Cites] Curr Biol. 2001 Jun 26;11(12):951-61 [11448771.001]
  • [Cites] Curr Biol. 2001 Aug 7;11(15):R592-5 [11516963.001]
  • [Cites] Dev Cell. 2001 Sep;1(3):423-34 [11702953.001]
  • [Cites] Genome Biol. 2002;3(1):REVIEWS3001 [11806834.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):878-89 [11840333.001]
  • [Cites] N Engl J Med. 2002 May 16;346(20):1513-21 [12015390.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):E172-3 [12105428.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):28-33 [12573432.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):429-34 [12649343.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1709-13 [12865297.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28067-78 [12740383.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):367-77 [12967557.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):47-59 [14555616.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):266-71 [14695885.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 21;318(1):259-64 [15110782.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):357-62 [9450748.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):95-9 [9724099.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1098-103 [15592505.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1728-31 [16646053.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):135-44 [17329407.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1843-8 [10777218.001]
  • (PMID = 21029453.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  • [Other-IDs] NLM/ PMC2990739
  •  go-up   go-down


9. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M: Involvement of PKC-iota in glioma proliferation. Cell Prolif; 2008 Feb;41(1):122-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of PKC-iota in glioma proliferation.
  • However, in vivo, the status and function of PKC-iota in human normal brain tissue, gliomas, benign and malignant meningiomas as well as its in vitro status in proliferating and confluent glioma cells, remains unknown.
  • OBJECTIVES: The objectives of our research were to determine whether expression of PKC-iota is altered either in gliomas or in benign and malignant meningiomas, compared to normal brain.
  • In addition, we wished to establish the expression of PKC-iota in proliferating plus in cell cycle-arrested glioma cell lines, as well as the relationship between PKC-iota siRNA on PKC-iota protein content and cell proliferation.
  • MATERIALS AND METHODS: Western blot analyses for PKC-iota were performed on 12 normal brain biopsies, 15 benign meningiomas, three malignant meningiomas and three gliomas.
  • RESULTS: Results demonstrated no (n = 9) or very weak (n = 3) detection of PKC-iota in normal brain tissue.
  • In comparison, PKC-iota was robustly present in the majority of the benign meningiomas.
  • Similarly, PKC-iota was abundant in all malignant meningiomas and gliomas.
  • Western blotting for PKC-iota in confluent or proliferating glioma cell lines depicted substantial quantities of PKC-iota in proliferating T98G and U-138MG glioma cells.
  • T98 and U-138 MG glioma cells treated with 100 nm PKC-iota siRNA had lower levels of cell proliferation compared to control siRNA-A and complete down-regulation of PKC-iota protein content.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Isoenzymes / metabolism. Protein Kinase C / metabolism
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. RNA, Small Interfering

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211289.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Small Interfering; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


10. Sugita Y, Ono T, Ohshima K, Niino D, Ito M, Toda K, Baba H: Brain surface spindle cell glioma in a patient with medically intractable partial epilepsy: a variant of monomorphous angiocentric glioma? Neuropathology; 2008 Oct;28(5):516-20
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain surface spindle cell glioma in a patient with medically intractable partial epilepsy: a variant of monomorphous angiocentric glioma?
  • We report a case of brain surface angiocentric glioma in a 6-year-old Japanese boy with medically intractable partial epilepsy.
  • At surgery, a yellowish tumor was localized in the superficial cortex.
  • Histologically, the tumor was predominantly composed of elongated astrocytic cells forming rings around blood vessels.
  • Tumor cells circumferential to vessels predominanted in low cellurarity areas, whereas radial alignment with perivascular pseudorosettes was observed in more cellular regions.
  • The tumor cells showed variable cytoplasmic immunoreactivity with GFAP.
  • These findings were more likely monomorphous angiocentric glioma, which was first described by Wang et al. in 2005.
  • However, in our case the tumor had a small foci of polymorphous appearance and a comparatively high MIB-1 labeling index (8%).
  • Therefore, the present case may be an atypical form of monomorphous angiocentric glioma.
  • However, no de novo anaplastic monomorphous angiocentric glioma similar to our case has yet been reported in the literature.
  • It remains to be determined whether the behavior of monomorphous angiocentric glioma is an example of benign biological characteristics or whether it more closely resembles a low-grade malignant tumor.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Epilepsies, Partial / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Malformations of Cortical Development / pathology. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179412.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Jalali R, Budrukkar A, Sarin R, Sharma DS: High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours. Radiother Oncol; 2005 Jan;74(1):37-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours.
  • BACKGROUND AND PURPOSE: To report local control and follow up outcome data of high precision conformal radiotherapy in childhood brain tumours.
  • MATERIALS AND METHODS: Between December 1999 and December 2002, 26 children (17 boys and 9 girls, median age 11.5 years) with incompletely excised or recurrent benign and low-grade brain tumours [13 craniopharyngiomas, 11 low-grade gliomas (LGG) and 2 others] were treated with three-dimensional (3D) conformal radiotherapy (CRT) (12 patients) and stereotactic conformal radiotherapy (SCRT) (14 patients).
  • A patient with chiasmatic glioma developed cystic degeneration and hydrocephalus 9 months after SCRT requiring cyst drainage and placement of a ventriculoperitoneal shunt.
  • CONCLUSION: High-precision conformal techniques delivering irradiation to a computer generated target volume employing 7-10 mm 3D margins beyond the visible tumour and/or resected tumour bed appear to be safe in children with incompletely resected or recurrent benign and low-grade brain tumours, based on these data.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Craniopharyngioma / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Brain Diseases / etiology. Child. Child, Preschool. Combined Modality Therapy. Cysts / etiology. Dose Fractionation. Female. Humans. Male. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683667.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between PTEN gene expression and differentiation of human glioma.
  • OBJECTIVE: To investigate the relationship between PTEN gene expression and differentiation of glioma.
  • MATERIAL AND METHODS: The quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) method was applied to detect PTEN mRNA levels in glioma tissues.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • According to the pathological examinations, PTEN mRNA levels were higher in the high differential glioma than the low differential glioma.
  • CONCLUSIONS: PTEN gene expression was suppressed in the glioma, which is related to the clinical-pathological results.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


13. Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, Deshpande D, Sarin R: Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):974-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy.
  • PURPOSE: To present the effect of radiotherapy doses to different volumes of normal structures on neurocognitive outcomes in young patients with benign and low-grade brain tumors treated prospectively with stereotactic conformal radiotherapy (SCRT).
  • METHODS AND MATERIALS: Twenty-eight patients (median age, 13 years) with residual/progressive brain tumors (10 craniopharyngioma, 8 cerebellar astrocytoma, 6 optic pathway glioma and 4 cerebral low-grade glioma) were treated with SCRT to a dose of 54 Gy in 30 fractions over 6 weeks.
  • Radiotherapy doses to other normal structures, including supratentorial brain, right temporal lobe, and frontal lobes, did not reveal any significant correlation.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cognition Disorders / etiology. Glioma / radiotherapy. Intelligence / radiation effects
  • [MeSH-minor] Adolescent. Astrocytoma / radiotherapy. Cerebellar Neoplasms / psychology. Cerebellar Neoplasms / radiotherapy. Child. Cognition / radiation effects. Craniopharyngioma / psychology. Craniopharyngioma / radiotherapy. Female. Humans. Male. Optic Nerve Glioma / radiotherapy. Prospective Studies. Radiotherapy, Conformal / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19864079.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Harada M, Ishihara Y, Itoh K, Yamanaka R: Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep; 2007 Mar;17(3):629-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
  • One promising modality in the treatment of malignant glioma is specific immunotherapy.
  • In this study, we searched for new target candidates in specific immunotherapy for malignant glioma by utilizing cDNA microarray technology to compare gene expressions in malignant glioma tissues to those in benign glioma and a panel of normal tissues.
  • RT-PCR showed that these three genes were expressed in the majority of glioma cell lines.
  • These antigen-derived 25 peptides, which had the ability to bind to human leukocyte antigen (HLA)-A24 molecules, were first screened for their ability to be recognized by the immunoglobulin G of glioma patients, and then tested for their potential to induce peptide-specific and glioma-reactive cytotoxic T lymphocytes (CTLs) from the peripheral blood mononuclear cells of HLA-A24+ glioma patients.
  • The results showed that the KIF1C149-158 and KIF3C512-520 peptides efficiently induced HLA-A24-restricted and glioma-reactive CD8+ T cells.
  • These results suggest the existence of KIF-reactive CTL precursors in glioma patients, and should facilitate the development of specific immunotherapies for malignant glioma.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Brain Neoplasms / immunology. Glioma / immunology. HLA-A Antigens / immunology. Kinesin / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Cancer Vaccines. Cell Line, Tumor. Gene Expression. Gene Expression Profiling. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunotherapy / methods. Oligonucleotide Array Sequence Analysis. Peptides / immunology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273744.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger; EC 3.6.1.- / Kinesin
  •  go-up   go-down


15. Kravets LIa, Trofimov AO: [Delayed surgical operations in benign supratentorial gliomas]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Jan-Mar;(1):24-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Delayed surgical operations in benign supratentorial gliomas].
  • Benign gliomas are slowly growing primary brain tumors with prolonged natural course and tendency to malignization.
  • The paper describes results of treatment of 19 patients with benign supratentorial gliomas.
  • Aspects of volume evolution and surgical excision of tumor are highlighted.
  • [MeSH-major] Glioma / surgery. Neurosurgical Procedures / methods. Supratentorial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505027.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


16. Matsuno A, Nagashima H, Ishii H, Iwamuro H, Nagashima T: Aggressive and invasive growth of tectal glioma after surgical intervention and chemoradiotherapy. Br J Neurosurg; 2006 Aug;20(4):246-9
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive and invasive growth of tectal glioma after surgical intervention and chemoradiotherapy.
  • A tectal glioma presenting with late-onset aqueduct stenosis and obstructive hydrocephalus is usually categorized as a benign glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Brain Stem. Glioma / therapy. Hydrocephalus / therapy. Ventriculostomy / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954079.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Hargrave D: Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg; 2009 Aug;23(4):351-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
  • Gliomas are the most common type of paediatric brain tumour and range from benign low grade gliomas which can be resected/observed to aggressive brainstem gliomas with dismal survival rates.
  • Current therapies rely on neurosurgery, radiotherapy, chemotherapy or combination of these conventional modalities and although histopathology helps to direct therapy, molecular pathology has so far not played a major role in the management of paediatric glioma.
  • However, increasing knowledge of glioma biology is starting to impact on drug development towards targeted therapies.
  • Pilocytic astrocytoma, the most common childhood low grade brain tumour, has recently been shown to harbour an activated BRAF/MAPK/ERK pathway in the majority of cases; this represents an attractive target for new agents.
  • The molecular biology of adult malignant glioma is now well described and targeted therapies against VEGFR are already playing a role in the management of glioblastoma.
  • It is likely that high grade gliomas in children and adults share common aberrant molecular pathways but the frequency and mechanisms involved probably will exhibit key differences and on-going comprehensive molecular analyses of paediatric high grade glioma are essential to determine which targets are important in children.
  • Brainstem glioma remains a tumour with a dismal prognosis but relatively little is known about the underlying biology and progress will require a concerted effort to collect tissue by biopsy and autopsy to allow appropriate analysis to identify and validate targets.
  • A new era of molecular based therapies offers the promise of major benefits in the management of paediatric glioma but translating this promise into reality will require further understanding of the biology driving these tumours.
  • [MeSH-major] Brain Neoplasms. Glioma / pathology


18. Qian ZY, Wu YY, Huang Q, Zhai DZ, Zhu Q, Wang AD, Huo HM, Lan Q: [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jun;30(6):432-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas].
  • METHODS: Tissue microarrays were constructed containing 118 samples including human glioma and meningioma, experimental glioma, and normal human brain tissue.
  • RESULTS: The expressions of SV40Tag, Rb and IRS-1 were detected in gliomas and benign brain tumors.
  • Their positive expression rate in glioma was 65.9%, 64.6% and 48.8%, respectively, with a statistically non-significant difference between the malignant and benign brain tumors.
  • The malignant degree was positively correlated with SV40Tag and IRS-1, but negatively correlated with Rb expression.
  • In the normal human brain tissue only the expression of Rb (77.8%, 7/9) and IRS-1 (22.2%, 2/9) were detected, but expression of SV40Tag could not be observed.
  • CONCLUSION: Our findings that no expression of SV40Tag was observed in normal human brain tissue indicates that expression of SV40Tag may play an important role in the pathogenesis of glioma.
  • It may be assumed that after SV40 virus invading human body, Rb disfunction and IRS-1 activation promote the malignant transformation of cells, which could be one of important factors in pathogenesis and procession of glioms.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Insulin Receptor Substrate Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Meningioma / metabolism. Meningioma / pathology. Mice. Middle Aged. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024517.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


19. Degaki TL, Demasi MA, Sogayar MC: Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line. J Steroid Biochem Mol Biol; 2009 Nov;117(4-5):107-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line.
  • Upon searching for glucocorticoid-regulated cDNA sequences associated with the transformed to normal phenotypic reversion of C6/ST1 rat glioma cells, we identified Nrp/b (nuclear restrict protein in brain) as a novel rat gene.
  • Among rat tissues, Nrp/b expression is more pronounced in brain tissue.
  • We show that overexpression of the Nrp/b cDNA in C6/ST1 cells suppresses anchorage independence in vitro and tumorigenicity in vivo, altering their malignant nature towards a more benign phenotype.
  • Therefore, Nrp/b may be postulated as a novel tumor suppressor gene, with possible relevance for glioblastoma therapy.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Microfilament Proteins / genetics. Neuropeptides / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Western. Cell Line, Tumor. Cloning, Molecular. DNA, Complementary. Gene Expression Regulation. Humans. Immunohistochemistry. Molecular Sequence Data. Rats. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682578.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Microfilament Proteins; 0 / Neuropeptides; 0 / Nuclear Proteins; 0 / ectodermal-neural cortex 1 protein
  •  go-up   go-down


20. Strojnik T, Kavalar R, Trinkaus M, Lah TT: Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev; 2005;29(5):448-55
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin L in glioma progression: comparison with cathepsin B.
  • OBJECTIVE: Lysosomal cysteine cathepsins have been implicated in tumor progression.
  • This study is aimed to reveal differential expression and compare the prognostic significance of cathepsins B and L in glioma patients.
  • We evaluated the immunostaining of the cathepsins in tumor and endothelial cells.
  • The total score was significantly higher in malignant than in benign tumors, both for cathepsin B (p<0.001) and for cathepsin L (p<0.01).
  • The IHC score in endothelial cells in the malignant group was significantly higher only for cathepsin B (p<0.0001).
  • CONCLUSION: Cathepsin L is preferentially expressed in tumor cells, increasing with glioma progression, but is not significantly associated with new vasculature of glioblastoma.
  • In contrast to cathepsin B, cathepsin L has no prognostic impact, suggesting different roles of the two cathepsins in glioma progression.
  • [MeSH-major] Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Cathepsin B / biosynthesis. Cathepsin B / physiology. Cathepsins / biosynthesis. Cathepsins / physiology. Cysteine Endopeptidases / biosynthesis. Cysteine Endopeptidases / physiology. Glioma / chemistry. Glioma / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183211.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


21. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application].
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


22. Min ZG, Liu HJ, Li M, Liu LH, Jin CW, Zhang M: [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2927-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis].
  • The factors that affected the diagnostic accuracy were the sample size, the ratio of malignant glioma, the injection rate of contrast agents, the repetition time and the cutoff value.
  • CONCLUSION: the relative cerebral blood volume (rCBV) of MR PWI can be referred to differentiate malignant cerebral gliomas from benign ones with sound sensitivity and specificity.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Spectroscopy

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211399.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


23. Callu D, Viguier D, Laroussinie F, Puget S, Boddaert N, Kieffer V, Piana H, Escolano S, Renier D, Sainte-Rose C, Grill J, Dellatolas G: Cognitive and academic outcome after benign or malignant cerebellar tumor in children. Cogn Behav Neurol; 2009 Dec;22(4):270-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive and academic outcome after benign or malignant cerebellar tumor in children.
  • OBJECTIVE: To examine the impact of malignancy and location of the cerebellar tumor on motor, cognitive, and psychologic outcome.
  • BACKGROUND: Although many studies focus on long-term outcome after cerebellar tumor treatment in childhood, the impact of its precise location remains unclear.
  • PATIENTS AND METHODS: Children, aged from 6 to 13 years, with a cerebellar malignant tumor (MT; MT group, n=20) or a cerebellar benign tumor (BT; BT group, n=19) were examined at least 6 months after the end of treatment using the international cooperative ataxia rating scale, the Purdue pegboard for manual skill assessment and the age-adapted Weschler scale.
  • Structural changes in brain anatomy were evaluated and parents and teachers answered 2 independent questionnaires.
  • RESULTS: Parents and teachers reported high rate of learning and academic difficulties, but without any difference with respect to the type of tumor.
  • [MeSH-major] Achievement. Cerebellar Neoplasms / therapy. Cognition. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996881.001).
  • [ISSN] 1543-3641
  • [Journal-full-title] Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
  • [ISO-abbreviation] Cogn Behav Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Alexiou GA, Varela M, Sfakianos G, Prodromou N: Benign lesions accompanied by intractable epilepsy in children. J Child Neurol; 2009 Jun;24(6):697-700
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign lesions accompanied by intractable epilepsy in children.
  • Epilepsy surgery has been proposed as a safe alternative treatment for intractable epilepsy in children, especially for patients with structural brain abnormalities.
  • The histopathological examination of the resected lesions revealed in 12 cases the presence of a ganglioglioma, in 7 cases dysembryoplastic neuroepithelial tumor, in 1 case a low grade glioma, in 2 cases cortical dysplasia, and in 2 cases cavernous malformations.
  • [MeSH-minor] Adolescent. Brain / pathology. Brain / surgery. Brain Neoplasms / complications. Brain Neoplasms / pathology. Cavernous Sinus / abnormalities. Child. Child, Preschool. Female. Follow-Up Studies. Ganglioglioma / complications. Ganglioglioma / pathology. Glioma / complications. Glioma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Malformations of Cortical Development / complications. Malformations of Cortical Development / pathology. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289694.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Della Puppa A, Rossetto M, Ciccarino P, Del Moro G, Rotilio A, Manara R, Paola Gardiman M, Denaro L, d'Avella D, Scienza R: The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. Acta Neurochir (Wien); 2010 Nov;152(11):1923-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
  • PURPOSE: Carmustine (1,3-bis[2-chloroetyl]-1-nitrosurea (BCNU)) wafers are approved for the local treatment of newly diagnosed and recurrent malignant glioma.
  • METHODS: Forty-three patients affected by malignant glioma underwent surgical removal and BCNU wafers implantation at the Department of Neurosurgery of Padova from April 2007 to October 2009.
  • In general, cysts presented a benign behaviour in the sense that patients promptly improved with corticosteroid treatment, never required surgery, never reported permanent neurological deficits.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Carmustine / administration & dosage. Glioma / drug therapy. Infusion Pumps, Implantable

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20703889.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


26. Demir C, Gultekin SH, Yener B: Learning the topological properties of brain tumors. IEEE/ACM Trans Comput Biol Bioinform; 2005 Jul-Sep;2(3):262-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Learning the topological properties of brain tumors.
  • This work presents a graph-based representation (a.k.a., cell-graph) of histopathological images for automated cancer diagnosis by probabilistically assigning a link between a pair of cells (or cell clusters).
  • Since the node set of a cell-graph can include a cluster of cells as well as individual ones, it enables working with low-cost, low-magnification photomicrographs.
  • First, it is shown that without establishing a pairwise spatial relation between the cells (i.e., the edges of a cell-graph), neither the spatial distribution of the cells nor the texture analysis of the images yields accurate results for tissue level diagnosis of brain cancer called malignant glioma.
  • In this work, the results are obtained on the photomicrographs of 646 archival brain biopsy samples of 60 different patients.
  • It is shown that the global metrics of cell-graphs distinguish cancerous tissues from noncancerous ones with high accuracy (at least 99 percent accuracy for healthy tissues with lower cellular density level, and at least 92 percent accuracy for benign tissues with similar high cellular density level such as nonneoplastic reactive/inflammatory conditions).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044189.001).
  • [ISSN] 1545-5963
  • [Journal-full-title] IEEE/ACM transactions on computational biology and bioinformatics
  • [ISO-abbreviation] IEEE/ACM Trans Comput Biol Bioinform
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


27. Hughes SA, Achanta P, Ho AL, Duenas VJ, Quiñones-Hinojosa A: Biological horizons for targeting brain malignancy. Adv Exp Med Biol; 2010;671:93-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological horizons for targeting brain malignancy.
  • Though currently available clinical treatments and therapies have clearly extended the survival of patients with brain tumors, many of these advances are short lived, particularly with respect to high grade gliomas such as glioblastoma multiforme.
  • The missing link to an efficacious treatment of high grade gliomas is a more complete understanding of the basic molecular and cellular origin of brain tumors.
  • However, new discoveries of stem cell and developmental neurobiology have now borne the cancer stem cell hypothesis, drawing off of intriguing similarities between benign and malignant cells within the central nervous system.
  • Investigation of cancer stem cell hypothesis and brain tumor propagation is the current frontier of stem cell and cancer biology.
  • "Molecular neurosurgery", glioma treatments involving biologics using neural stem cells to target the cancer at the level of individual migratory cell, is a rapidly evolving field.
  • This coming progression of applied cancer stem cell research, coupled with current modalities, promises more comprehensive brain cancer interventions.
  • [MeSH-major] Brain Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Drug Delivery Systems. Genetic Therapy / methods. Glioma / pathology. Glioma / therapy. Neurons / physiology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455498.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • We observed that glioma patients presented higher NCAM HMW and lower NCAM LMW levels than control subjects (P < 0.01).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • We observed that NCAM immunostaining was inversely correlated with the histological grade of malignancy, remaining this association in a multivariate analysis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


29. Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, Tatsch K: Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging; 2006 Jul;33(7):792-800
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.
  • PURPOSE: Intracavitary radioimmunotherapy (RIT) offers an effective adjuvant therapeutic approach in patients with malignant gliomas.
  • METHODS: Following conventional therapy, 24 glioma patients (5 WHO III, 19 WHO IV) underwent one to five RIT cycles with either (131)I-labelled (n=19) or (188)Re-labelled (n=5) anti-tenascin antibodies.
  • Homogeneous, slightly increasing FET uptake around the tumour cavity with a peak up to 18 months after RIT, followed by stable or decreasing uptake, points to benign, therapy-related changes.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / radiotherapy. Glioma / radionuclide imaging. Glioma / radiotherapy. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan;12(1):45-62 [7502957.001]
  • [Cites] Eur J Nucl Med. 1996 May;23(5):583-6 [8698067.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):345-53 [8938309.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2733-42 [9406732.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):26-33 [9407628.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 May;18(5):500-9 [9591842.001]
  • [Cites] J Nucl Med. 1998 Aug;39(8):1376-80 [9708511.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1367-73 [10450690.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70 [15248032.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):678-87 [15689365.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9 [15650870.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1931-8 [15534065.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):542-9 [10853810.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):601-9 [10853818.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 May;29(5):648-54 [11976803.001]
  • [Cites] Nuklearmedizin. 2002 Jun;41(3):120-8 [12109031.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1056-64 [12744366.001]
  • [Cites] J Neurooncol. 2003 May;62(3):321-8 [12777085.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):437-48 [15056451.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1469-73 [15083170.001]
  • [Cites] Invest Radiol. 1979 Mar-Apr;14(2):109-21 [478799.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • (PMID = 16550381.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine
  • [Other-IDs] NLM/ PMC1998889
  •  go-up   go-down


30. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ: 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med; 2006 May;47(5):776-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FET PET differentiation of ring-enhancing brain lesions.
  • In all patients, the main differential diagnosis after MRI was a malignant lesion, in particular glioblastoma multiforme, versus a benign lesion, in particular brain abscess.
  • A malignant tumor was suspected for lesions showing increased (18)F-FET uptake on PET images with a mean lesion-to-brain ratio of at least 1.6 ((18)F-FET PET positive).
  • A nonneoplastic lesion was suspected in cases of minimal or absent (18)F-FET uptake, with a mean lesion-to-brain ratio of less than 1.6 ((18)F-FET PET negative).
  • Histologic diagnosis was obtained by serial biopsies in 13 of the 14 patients.
  • RESULTS: Histology and clinical follow-up showed high-grade malignant gliomas in 5 patients and nonneoplastic lesions in 9 patients.
  • The findings of (18)F-FET PET were positive in all 5 glioma patients and in 3 of 9 patients with nonneoplastic lesions, including 2 patients with brain abscesses and 1 patient with a demyelinating lesion.
  • The findings of (18)F-FDG PET were positive (mean lesion-to-gray matter ratio > or = 0.7) in 4 of 4 glioma patients and 3 of 7 patients with nonneoplastic lesions.
  • CONCLUSION: Although (18)F-FET PET has been shown to be valuable for the diagnostic evaluation of brain tumors, our data indicate that, like (18)F-FDG PET, (18)F-FET PET has limited specificity in distinguishing between neoplastic and nonneoplastic ring-enhancing intracerebral lesions.
  • Thus, histologic investigation of biopsy specimens remains mandatory to make this important differential diagnosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiopharmaceuticals / pharmacology. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644747.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Sugo N, Yokota K, Kondo K, Harada N, Aoki Y, Miyazaki C, Nemoto M, Kano T, Ohishi H, Seiki Y: Early dynamic 201Tl SPECT in the evaluation of brain tumours. Nucl Med Commun; 2006 Feb;27(2):143-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early dynamic 201Tl SPECT in the evaluation of brain tumours.
  • OBJECTIVE: To estimate the usefulness of early dynamic 201Tl single photon emission computed tomography (SPECT) studies in distinguishing the histological malignancy of brain tumours.
  • METHODS: Dynamic 201Tl SPECT was performed for 3 min per scan for 15 min immediately after the administration of 201TlCl in 110 patients with brain tumours (111 lesions).
  • For static SPECT, the static thallium index (STI) was calculated as the ratio of 201Tl uptake in the tumour to that of the contralateral normal brain.
  • RESULTS: In static SPECT, there was no significant difference between the STI of malignant tumours (glioblastoma and anaplastic astrocytoma) and that of benign tumours (low-grade glioma, meningioma, pituitary adenoma, neurinoma and haemangioblastoma) (3.7+/-1.5, 5.0+/-3.5, respectively).
  • On dynamic SPECT, DTI increased markedly over 15 min for malignant tumours.
  • In contrast, the DTI of benign tumours increased slightly, steadily or decreased.
  • The slope of the linear functions calculated from the DTRs was much higher in the malignant tumour group than in the benign tumour group (P<0.001).
  • CONCLUSIONS: We suggest that the performance of 201Tl dynamic SPECT for 15 min is useful for distinguishing malignant brain tumours from benign brain tumours and reduces the examination stress of patients.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / radionuclide imaging. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Severity of Illness Index. Thallium. Tomography, Emission-Computed, Single-Photon / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404227.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium
  •  go-up   go-down


33. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, Oya N, Mukai T, Hojo M, Hashimoto N, Manabe T, Hiraoka M, Togashi K: Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med; 2006 Dec;31(12):774-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of primary brain tumors with FLT-PET: usefulness and limitations.
  • PURPOSE OF THE REPORT: The purpose of this report was to investigate the potential of positron emission tomography using F-18 fluorodeoxythymidine (FLT-PET) in evaluating primary brain tumors.
  • MATERIALS AND METHODS: FLT-PET was performed in 25 patients with primary brain tumors.
  • FLT uptake in the lesion was semiquantitatively evaluated by measuring the maximal standardized uptake value (SUVmax) and the tumor-to-normal tissue ratio (TNR).
  • SUVmax and TNR were compared with the histologic grade and the expression of the proliferation marker (Ki-67).
  • RESULTS: FLT uptake in normal brain parenchyma was very low, resulting in the visualization of brain tumors with high contrast.
  • Both SUVmax and TNR significantly correlated with the malignant grade of brain gliomas, in which high SUVmax/TNR was obtained for high-grade gliomas.
  • In contrast, spuriously high SUVmax and TNR were obtained in 3 of 6 patients with suspected recurrent tumors (2 patients with recurrent grade 2 glioma and one patient with postoperative granuloma), all of which showed lesion enhancement on MRI after Gd administration.
  • CONCLUSIONS: FLT-PET can be used to evaluate the malignant grade and proliferation activity of primary brain tumors, especially malignant brain tumors.
  • However, the presence of benign lesions showing blood-brain barrier disruption cannot be distinguished from malignant tumors and needs to be carefully evaluated.
  • [MeSH-major] Brain / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Dideoxynucleosides

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117071.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; PG53R0DWDQ / alovudine
  •  go-up   go-down


34. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ: Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci; 2010 Jan;17(1):43-9
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
  • The aim of this prospective pilot study in patients with suspected or known brain tumour was to establish the diagnostic value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) when compared to fluorine-18 fluorodeoxyglucose (FDG) PET.
  • Final malignant pathology included 11 glioma (eight low-grade, three high grade), two lymphoma, one olfactory ganglioneuroblastoma, one anaplastic meningioma.
  • Benign pathology included two encephalitis and one cortical dysplasia.
  • FET PET is more accurate than FDG PET for detecting malignant brain lesions, especially low-grade gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radioisotopes. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Brain / pathology. Brain / physiopathology. Brain / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Glioma / metabolism. Glioma / pathology. Glioma / radionuclide imaging. Humans. Lymphoma / metabolism. Lymphoma / pathology. Lymphoma / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20004582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / O-(2-((18)F)fluoroethyl)-L-tyrosine; 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


35. Novak L, Molnar P, Lengyel Z, Tron L: Does increased 18FDG uptake reflect malignant transformation of a low-grade glioma? A diagnostic dilemma. Neurol India; 2005 Mar;53(1):112-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does increased 18FDG uptake reflect malignant transformation of a low-grade glioma? A diagnostic dilemma.
  • Benign gliomas of the brain show decreased uptake of 18F fluorodeoxyglucose (FDG) on positron emission tomography (PET).
  • Malignant transformation is usually manifested by an increase of 18FDG uptake.
  • A 45-year-old female has been followed up since 1987 by means of 18FDG-PET for a right hemispheric World Health Organization Grade II oligoastrocytoma.
  • In 1996, increased epileptic activity was accompanied by increased 18FDG uptake within the temporal part of the tumor.
  • Histological examination of the resected tumor showed no change in the pathology when compared with the first biopsy.
  • Localized temporal increase of 18FDG uptake was not associated with malignant progression.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glioma / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805670.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Evans CL, Xu X, Kesari S, Xie XS, Wong ST, Young GS: Chemically-selective imaging of brain structures with CARS microscopy. Opt Express; 2007 Sep 17;15(19):12076-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemically-selective imaging of brain structures with CARS microscopy.
  • We demonstrate the use of coherent anti-Stokes Raman scattering (CARS) microscopy to image brain structure and pathology ex vivo.
  • Although non-invasive clinical brain imaging with CT, MRI and PET has transformed the diagnosis of neurologic disease, definitive pre-operative distinction of neoplastic and benign pathologies remains elusive.
  • Definitive diagnosis still requires brain biopsy in a significant number of cases.
  • These attributes make CARS an ideal technique for fast, minimally invasive, non-destructive, molecularly specific intraoperative optical diagnosis of brain lesions.
  • This promises significant clinical benefit to neurosurgical patients by providing definitive diagnosis of neoplasia prior to tissue biopsy or resection.
  • CARS imaging can augment the diagnostic accuracy of traditional frozen section histopathology in needle biopsy and dynamically define the margins of tumor resection during brain surgery.
  • This report illustrates the feasibility of in vivo CARS vibrational histology as a clinical tool for neuropathological diagnosis by demonstrating the use of CARS microscopy in identifying normal brain structures and primary glioma in fresh unfixed and unstained ex vivo brain tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547572.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ, Langen KJ: Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med; 2008 May;49(5):730-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.
  • Nonspecific incidental brain lesions (NILs) are being detected more frequently because of an increasing number of screening or research MRI scans of the brain, and their natural course is uncertain.
  • Patients with seizures, focal neurologic deficits, signs of local or systemic infection or inflammation, known brain disease, or any kind of previous cerebral treatment were excluded.
  • Mean lesion-to-brain (L/B) ratios of >or=1.6 on (18)F-FET PET were rated as positive.
  • In group C, 2 NILs grew slowly over years, and an astrocytoma of World Health Organization (WHO) grade II was diagnosed after resection in each case.
  • In group D, 4 NILs showed sudden and rapid growth, with clinical deterioration, and a high-grade glioma of WHO grade III or IV was diagnosed after resection in all cases.
  • CONCLUSION: For NILs, a circumscribed growth pattern on MRI and normal or low (18)F-FET uptake on PET are strong predictors for a benign course, with the eventual development of a low-grade glioma.
  • In contrast, NILs with a diffuse growth pattern on MRI and increased (18)F-FET uptake indicate a high risk for the development of a high-grade glioma.
  • [MeSH-major] Brain / pathology. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease Progression. Female. Glioma / metabolism. Glioma / pathology. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413396.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


38. Watanabe T, Yachi K, Ohta T, Fukushima T, Yoshino A, Katayama Y, Shinojima Y, Terui T, Nagase H: Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors. Neurol Med Chir (Tokyo); 2010;50(12):1062-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors.
  • Comprehensive methylation analysis of tumor-specific differentially methylated regions in human malignant melanoma has recently led to the identification of non-promoter hypermethylation of the ZAR1 gene that had never been previously linked to aberrant methylation.
  • Strikingly, ZAR1 hypermethylation was frequently observed in melanomas but was absent in benign nevi, and ZAR1 expression was found to be up-regulated in methylated tumors.
  • The present study searched for non-promoter ZAR1 hypermethylation in 90 primary human brain tumor samples, normal brain tissue from one autopsy case, and 7 glioma cell lines, employing Sequenom MassARRAY, in which bisulfite-treated fragments are quantitatively detected using time-of-flight mass spectroscopy.
  • ZAR1 transcript expression levels were also evaluated by quantitative real-time reverse transcription-polymerase chain reaction in the 7 glioma cell lines.
  • Other tumor types showed infrequent ZAR1 hypermethylation: 1 (17%) of 6 vestibular schwannomas and 4 (33%) of 12 meningothelial meningiomas.
  • The normal brain tissue revealed no evidence of ZAR1 methylation.
  • All 7 glioma cell lines displayed aberrant hypermethylation of ZAR1, but none had detectable ZAR1 transcript.
  • Our findings indicate that non-promoter hypermethylation of ZAR1 is extremely frequent in diffuse gliomas and pituitary adenomas, but methylation-related aberrant ZAR1 expression is far less likely to be related to glioma tumorigenesis.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Egg Proteins / metabolism. Glioma / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Case-Control Studies. Cell Line, Tumor. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Mass Spectrometry. Melanoma / metabolism. Melanoma / pathology. Methylation. Nevus / metabolism. Nevus / pathology. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Reference Values

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206179.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Egg Proteins; 0 / Zar1 protein, human
  •  go-up   go-down


39. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Proportional hazard regression showed that only WHO grading class (low versus high) was predictive of survival (P = .015).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


40. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • The 6 remaining cases showed features seen in between glioneuronal hamartoma and mixed neuronal-glial tumor.
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • The similar morphologic pattern and biological behavior of glioneuronal hamartoma and mixed neuronal-glial tumor may suggest a common pathogenetic mechanism.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


41. Georgiadis P, Cavouras D, Kalatzis I, Glotsos D, Athanasiadis E, Kostopoulos S, Sifaki K, Malamas M, Nikiforidis G, Solomou E: Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods. Magn Reson Imaging; 2009 Jan;27(1):120-30
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods.
  • Three-dimensional (3D) texture analysis of volumetric brain magnetic resonance (MR) images has been identified as an important indicator for discriminating among different brain pathologies.
  • The purpose of this study was to evaluate the efficiency of 3D textural features using a pattern recognition system in the task of discriminating benign, malignant and metastatic brain tissues on T1 postcontrast MR imaging (MRI) series.
  • The dataset consisted of 67 brain MRI series obtained from patients with verified and untreated intracranial tumors.
  • The latter, in conjunction with using 3D textural features, enabled boosting up the performance of the system in discriminating metastatic, malignant and benign brain tumors with 77.14%, 89.19% and 93.33% accuracy, respectively.
  • The proposed system might be used as an assisting tool for brain tumor characterization on volumetric MRI series.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Pattern Recognition, Automated / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Least-Squares Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602785.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Unlike the abundantly expressed CB1, the CB2 receptor shows a restricted distribution in normal brain.
  • Although brain tumors constitute the second most common malignancy in children and the prevalence of histological types of brain tumors vary significantly between the adult and pediatric populations, cannabinoid receptor expression in pediatric tumors remains unknown.
  • In the present study, we compared the expression of the CB2 receptor in paraffin-embedded sections from primary brain tumors of adult and pediatric patients.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • In contrast, all examined cases of embryonal tumors (medulloblastoma and S-PNET), the most frequently diagnosed malignant brain tumors in childhood, showed no or trace CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Receptor, Cannabinoid, CB2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


43. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F, Lin X: Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun; 2008 Apr;29(4):354-8
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours.
  • BACKGROUND AND OBJECTIVE: The widely applied F-FDG is known for its disadvantage in brain tumour PET imaging because of its high background uptake.
  • C-choline can achieve high contrast of brain tumour imaging and was expected to have higher sensitivity and specificity.
  • We analysed the misdiagnoses in C-choline PET imaging in brain tumours with the aim of improving the accuracy of diagnosis with C-choline PET imaging.
  • PATIENTS AND METHODS: We selected 10 patients proven to have been misdiagnosed on the basis of histopathological correlation and clinical follow-up among 94 patients (110 studies) who underwent C-choline PET/CT for diagnosed or suspected brain tumour between 23 March 2005 and 8 February 2007.
  • RESULTS: Of all 10 misdiagnosed patients, five were false positive (one abscess, one tuberculosis, one benign gliocyte proliferation, one inflammatory granuloma and one demyelination), four were false negative (two metastases from lung cancer, one lymphoma, one grade II glioma) and one was misdiagnosed by wrong interpretation due to lack of experience.
  • With proper application, C-choline might have greater potential than F-FDG for brain tumour PET imaging.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Choline. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317300.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; N91BDP6H0X / Choline
  •  go-up   go-down


44. Fayed N, Modrego PJ: The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol; 2005 May;72(3):261-5
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours.
  • Conventional Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are the cornerstone in the initial evaluation of brain tumours.
  • The purpose of this study is to evaluate the contribution of Magnetic Resonance Spectroscopy (MRS) and Perfusion-weighted MRI to distinguish malignant from benign tumours.
  • We included 55 patients diagnosed with single brain tumour by CT and MRI, and final histopathological verification of the tumour type: 25 were low-grade gliomas, 8 anaplastic gliomas, 11 glioblastomas, and 11 solitary metastases.
  • We carried out brain MRS and dynamic perfusion-weighted echoplanar MRI in all cases.
  • In MRS, we found significant differences in Choline/Creatine ratios in relation to the tumour type with the highest values in high-grade gliomas and metastases.
  • We found no significant differences in the relative cerebral blood volume (rCBV) for every type of tumour.
  • The mean rCBV was 1.24 for benign tumours and 1.5 for the malignant ones(1.24 for low-grade gliomas, 1.91 for anaplastic gliomas, 1.03 for glioblastomas, and 1.57 for metastases).
  • We conclude that, individually considered, MRS is superior to Perfusion-weighted MRI in the initial assessment of brain tumours.
  • Perfusion MRI has not demonstrated predictive power to distinguish malignant from benign tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Echo-Planar Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / chemistry. Astrocytoma / diagnosis. Astrocytoma / pathology. Blood Volume / physiology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Creatinine / metabolism. Female. Glioma / chemistry. Glioma / diagnosis. Glioma / pathology. Humans. Lactates / metabolism. Male. Middle Aged. Neoplasm Metastasis / diagnosis. ROC Curve. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937650.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lactates; AYI8EX34EU / Creatinine; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


45. Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A: Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol; 2009 Dec;95(3):413-419
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.
  • The aim of this article is to evaluate and assess the impact of various factors on quality of life (QOL) in adult patients with primary brain tumors seen consecutively in routine neurooncology practice.
  • Two hundred and fifty-seven adult patients, after undergoing surgical intervention and histologically proven primary brain neoplasms were registered in the NeuroOncology Clinic at our centre during 1 full calendar year.
  • The study included detailed neurological assessment, evaluation of QOL using EORTC questionnaire (QLQ-30) and specific Brain Cancer module (BN 20).
  • In the present analysis, QOL scores before starting adjuvant treatment were measured and impact of patient and tumor related factors were analyzed.
  • Baseline global QOL data of all patients (available in 243) was relatively low including in all histological tumor types.
  • Domains of future uncertainty, visual disorder, motor deficit, communication deficit, headache, seizures and drowsiness scores were 19.6, 18.2, 28.5, 30.7, 21, 31.8 and 16 (lower values better), respectively.
  • Patients with lower performance status (KPS < 70) had a lower global QOL (KPS >or= 80 vs. <or= 70; 37 vs. 67; p = 0.001) including in all histological types of high-grade gliomas (HGG) (p = 0.005), low-grade gliomas (LGG) (p = 0.04) and benign tumors (p = <0.001).
  • Tumor type is an important patient related factor that influences baseline global scores (LGG vs. HGG 62 and 52; p = 0.015).
  • Type of surgery (biopsy/complete excision) (p = 0.284) and site of tumor (p = 0.309) did not show any impact on QOL score.
  • Patients with primary brain tumours before starting adjuvant therapy have relatively low baseline quality of life scores, especially in lower economic and literacy strata.
  • Patients with malignant tumors and poor performance status had significantly lower QOL scores even before starting adjuvant treatment.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Outpatient Clinics, Hospital. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548070.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


47. Mentzel HJ, Seidel J, Fitzek C, Eichhorn A, Vogt S, Reichenbach JR, Zintl F, Kaiser WA: Pediatric brain MRI in neurofibromatosis type I. Eur Radiol; 2005 Apr;15(4):814-22
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric brain MRI in neurofibromatosis type I.
  • In addition to multiple peripheral neurofibromas, NF I predisposed to CNS tumors including optic glioma, astrocytoma and plexiform neurofibroma.
  • The purpose of this pictorial review is to illustrate characteristic brain MR imaging lesions in children with NF I and to give some recommendations about diagnostic imaging procedures in children suffering from NF I.
  • Typical findings in brain MRI are hyperintense lesion on T2-weighted images, so-called unknown bright objects, which may be useful as an additional imaging criterion for NF I.
  • Contrast administration is necessary in MR studies to maximize tumor detection and characterization, to add confidence to the diagnosis of benign probable myelin vacuolization, and to document stability of neoplasm on follow-up examinations.
  • The frequency of follow-up in children with known brain tumors will vary with the tumor grade, biological activity and treatment.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Neurofibromatosis 1 / pathology


48. Hourani R, Horská A, Albayram S, Brant LJ, Melhem E, Cohen KJ, Burger PC, Weingart JD, Carson B, Wharam MD, Barker PB: Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging; 2006 Feb;23(2):99-107
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.
  • PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children.
  • MATERIALS AND METHODS: Thirty-two children (20 males and 12 females, mean age = 10 +/- 5 years) with primary brain lesions were evaluated retrospectively.
  • Nineteen patients had a neuropathologically confirmed brain tumor, and 13 patients had a benign lesion.
  • RESULTS: Considering all possible combinations of metabolite ratios, the best discriminant function to differentiate between nonneoplastic lesions and brain tumors was found to include only the ratio of Cho/Cr (Wilks' lambda, P = 0.012; 78.1% of original grouped cases correctly classified).
  • The best discriminant function to differentiate between high- and low-grade tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified).
  • Cr levels in low-grade tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-grade tumors.
  • CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic value, particularly for inoperable or inaccessible lesions.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Germinoma / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 Wiley-Liss, Inc.
  • (PMID = 16374884.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS042851; United States / NCRR NIH HHS / RR / P41RR15241
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ: Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol; 2009 Oct;36(7):779-87
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
  • The purpose of this study was to compare the diagnostic value of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose ((18)F-FDG) and O-(2-[(18)F]fluoroethyl)-l-tyrosine ((18)F-FET) in patients with brain lesions suspicious of cerebral gliomas.
  • METHODS: Fifty-two patients with suspicion of cerebral glioma were included in this study.
  • The cerebral accumulation of (18)F-FDG was calculated by decay corrected subtraction of the (18)F-FET scan from the (18)F-FET/(18)F-FDG scan.
  • RESULTS: Histology revealed 24 low-grade gliomas (LGG) of World Health Organization (WHO) Grade II and 19 high-grade gliomas (HGG) of WHO Grade III or IV, as well as nine others, mainly benign histologies.
  • The gliomas showed increased (18)F-FET uptake (>normal brain) in 86% and increased (18)F-FDG uptake (>white matter) in 35%. (18)F-FET PET provided diagnostically useful delineation of tumor extent while this was impractical with (18)F-FDG due to high tracer uptake in the gray matter.
  • A local maximum in the tumor area for biopsy guidance could be identified with (18)F-FET in 76% and with (18)F-FDG in 28%.
  • In some benign lesions like abscesses, increased uptake was observed for both tracers indicating a limited specificity of both techniques.
  • CONCLUSIONS: (18)F-FET PET is superior to (18)F-FDG for biopsy guidance and treatment planning of cerebral gliomas.
  • The uptake of (18)F-FDG is associated with prognosis, but the predictive value is limited and a histological evaluation of tumor tissue remains necessary.
  • Therefore, amino acids like (18)F-FET are the preferred PET tracers for the clinical management of cerebral gliomas.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720290.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


50. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140507.001).
  • [ISSN] 0924-9338
  • [Journal-full-title] European psychiatry : the journal of the Association of European Psychiatrists
  • [ISO-abbreviation] Eur. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


51. Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P: Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery; 2005 Jun;56(6):1234-41; discussion 1241-2
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study.
  • In a 5-year follow-up study, we investigated the association of depression with survival of patients with a primary brain tumor.
  • METHODS: The study population consisted of 75 patients with a solitary primary brain tumor treated surgically at the Oulu Clinic for Neurosurgery, Oulu University Hospital, in Northern Finland.
  • The patients were interviewed during admission to the hospital for the tumor surgery.
  • Information on all deaths within 60 months after tumor operation was collected from the Cause of Death Register, provided by Statistics Finland.
  • RESULTS: The patients with a high-grade glioma had a survival time of 22.5 months (standard deviation, 21.4 mo), whereas the corresponding time was 50.2 months (standard deviation, 19.9 mo) for patients with a low-grade glioma and 58.2 months (standard deviation, 9.4 mo) for the patients with a histologically benign tumor (P < 0.001, difference between groups, Kruskal-Wallis test).
  • In the subgroup of patients with low-grade gliomas, depressive patients had a significantly shorter survival time compared with nondepressive subjects (P = 0.031, Kaplan-Meier survival analysis).
  • A corresponding difference was not found in patients with high-grade gliomas or benign tumors.
  • Tumor location in one hemisphere compared with bilateral location and wider extent of tumor surgery was associated with better survival in patients with low-grade gliomas and benign tumors but not in patients with high-grade gliomas.
  • CONCLUSION: Preoperative depression seemed to be a significant prognostic factor for worse survival in low-grade glioma patients.
  • In clinical practice, an evaluation of depression among brain tumor patients by structured and standardized diagnostic methods is needed to distinguish the patients whose depression actually needs treatment.
  • The effective treatment of clinical depression among brain tumor patients and the impact of treatment on the patients' chances of survival should be a focus of future research.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Depression / etiology. Depression / mortality. Neurosurgery / methods. Postoperative Complications

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918939.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Rosenberg DS, Demarquay G, Jouvet A, Le Bars D, Streichenberger N, Sindou M, Kopp N, Mauguière F, Ryvlin P: [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms. J Neurol Neurosurg Psychiatry; 2005 Dec;76(12):1686-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms.
  • BACKGROUND AND OBJECTIVES: Brain tumours responsible for longstanding partial epilepsy are characterised by a high prevalence of dysembryoplastic neuroepithelial tumour (DNT), whose natural evolution is much more benign than that of gliomas.
  • The preoperative diagnosis of DNT, which is not yet feasible on the basis of available clinical and imaging data, would help optimise the therapeutic strategy for this type of tumour.
  • This study tested whether [(11)C]-methionine positron emission tomography (MET-PET) could help to distinguish DNTs from other epileptogenic brain tumours.
  • METHODS: Prospective study of 27 patients with partial epilepsy of at least six months duration related to a non-rapidly progressing brain tumour on magnetic resonance imaging (MRI).
  • CONCLUSION: Normal MET-PET findings in patient with an epileptogenic and non-rapidly progressing brain tumour are suggestive of DNT, whereas a markedly increased tumour methionine uptake makes this diagnosis unlikely.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Epilepsy / etiology. Glioma / radionuclide imaging. Neoplasms, Neuroepithelial / radionuclide imaging. Teratoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1994 Jun;117 ( Pt 3):461-75 [8032857.001]
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):240-4 [12913847.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] J Neurooncol. 1994;22(3):275-9 [7760107.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurol Sci. 1995 Sep;132(1):20-7 [8523026.001]
  • [Cites] Ann Pathol. 1996;16(3):174-81 [8766174.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):47-53 [8998857.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):345-53 [8938309.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):276-87; discussion 287-8 [9007859.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):79-84 [9210054.001]
  • [Cites] J Neurooncol. 1998 Feb;36(3):279-83 [9524106.001]
  • [Cites] Neurosurg Rev. 1998;21(1):31-5 [9584283.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 May;19(5):801-6 [9613489.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1103-7 [10587156.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]
  • [Cites] Epilepsia. 2004 Jan;45(1):41-5 [14692906.001]
  • [Cites] Neurology. 1982 Dec;32(12):1323-9 [6983044.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jul-Aug;9(4):683-9 [3926834.001]
  • [Cites] AJNR Am J Neuroradiol. 1985 Jul-Aug;6(4):505-14 [2992257.001]
  • [Cites] J Neurooncol. 1986;3(4):397-404 [3485705.001]
  • [Cites] J Comput Assist Tomogr. 1987 Mar-Apr;11(2):208-13 [3493274.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):421-3 [3258029.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):616-22 [2013802.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):85-91 [2022975.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Nucl Med. 1993 Nov;34(11):1936-43 [8229238.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):283-95 [8293188.001]
  • [Cites] Brain Pathol. 1993 Oct;3(4):371-80 [8293193.001]
  • [Cites] Acta Neuropathol. 1993;86(5):433-8 [8310793.001]
  • [Cites] Histopathology. 1999 Apr;34(4):342-56 [10231402.001]
  • [Cites] J Child Neurol. 1999 Oct;14(10):673-7 [10511341.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]
  • [Cites] Eur J Nucl Med. 2000 Jul;27(7):778-87 [10952489.001]
  • [Cites] Clin Nucl Med. 2000 Sep;25(9):694-7 [10983756.001]
  • [Cites] Ann Pathol. 2000 Oct;20(5):429-37 [11084410.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Neuroradiol. 2001 Dec;28(4):230-40 [11924137.001]
  • [Cites] Epileptic Disord. 2002 Jun;4(2):99-119 [12105073.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] Neurosurgery. 1994 May;34(5):815-23; discussion 823-4 [8052378.001]
  • (PMID = 16291894.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  • [Other-IDs] NLM/ PMC1739454
  •  go-up   go-down


53. Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds PC, Pietsch T: Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia; 2009 Jul;11(7):700-11
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood.
  • High-grade gliomas (HGGs) of childhood represent approximately 7% of pediatric brain tumors.
  • In the current study, to identify aberrantly methylated genes that may be involved in the tumorigenesis of pediatric HGGs, we performed a microarray-based differential methylation hybridization approach and found frequent hypermethylation of the LHX9 (human Lim-homebox 9) gene encoding a transcription factor involved in brain development.
  • Bisulfite genomic sequencing and combined bisulfite restriction analysis showed that HGGs were frequently methylated at two CpG-rich LHX9 regions in comparison to benign, nondiffuse pilocytic astrocytomas and normal brain tissues.
  • This epigenetic modification was reversible by pharmacological inhibition (5-aza-2'-deoxycytidine), and reexpression of LHX9 transcript was induced in pediatric glioma cell lines.
  • Exogenous expression of LHX9 in glioma cell lines did not directly affect cell proliferation and apoptosis but specifically inhibited glioma cell migration and invasion in vitro, suggesting a possible implication of LHX9 in the migratory phenotype of HGGs.
  • Our results demonstrate that the LHX9 gene is frequently silenced in pediatric malignant astrocytomas by hypermethylation and that this epigenetic alteration is involved in glioma cell migration and invasiveness.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation / genetics. Glioma / genetics. Homeodomain Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2000;17(2):49-56 [11210171.001]
  • [Cites] Genomics. 2000 Mar 15;64(3):307-17 [10756098.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8375-80 [11731411.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):275-81 [11895042.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5496-503 [12154410.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:s175-84 [12456310.001]
  • [Cites] Gene Expr Patterns. 2002 Dec;2(3-4):373-7 [12617828.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1151-61 [15466382.001]
  • [Cites] Trends Genet. 1994 Sep;10(9):315-20 [7974745.001]
  • [Cites] C R Acad Sci III. 1995 Mar;318(3):295-306 [7788499.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Brain Pathol. 1998 Jan;8(1):13-8 [9458162.001]
  • [Cites] Bioessays. 1998 Jan;20(1):58-69 [9504048.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):783-93 [9880598.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):459-70 [9949205.001]
  • [Cites] Bioinformatics. 1999 May;15(5):356-61 [10366655.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):193-9 [15799819.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):5018-26 [16732332.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):315-21 [16645718.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):368-81 [17591937.001]
  • [Cites] Mol Vis. 2007;13:1483-95 [17893672.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • (PMID = 19568415.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / LHX9 protein, human; 0 / LIM-Homeodomain Proteins; 0 / RNA, Messenger; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2697356
  •  go-up   go-down


54. Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C: [Histological and molecular classification of gliomas]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):505-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main histological subtype of grade I gliomas are pilocytic astrocytomas, which are benign.
  • Diffuse astrocytomas, oligodendrogliomas and oligoastrocytomas are low-grade (II) or high-grade (III and IV) tumors.
  • Glioblastomas correspond to grade IV astrocytomas. C.
  • Daumas-Duport et al. have proposed another classification based on histology and imaging data, which distinguishes oligodendrogliomas and mixed gliomas of grade A (without endothelial proliferation and/or contrast enhancement), oligodendrogliomas and mixed gliomas of grade B (with endothelial proliferation or contrast enhancement), glioblastomas and glioneuronal malignant tumors.
  • De novo glioblastomas, which occur in young patients without of a prior history of brain tumor and harbor frequent amplification of EGFR, deletion of p16 and mutation of PTEN while mutation of p53 is infrequent.
  • Secondary glioblastomas occur in the context of a preexisting low-grade glioma and are characterized by more frequent mutation of p53.
  • However, histological and molecular classifications do not always correspond as many alterations are shared by high-grade tumors, whatever their histological type.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology


55. Riemenschneider MJ, Reifenberger G: Molecular neuropathology of gliomas. Int J Mol Sci; 2009 Jan;10(1):184-212
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common primary human brain tumors.
  • They comprise a heterogeneous group of benign and malignant neoplasms that are histologically classified according to the World Health Organization (WHO) classification of tumors of the nervous system.
  • Over the past 20 years the cytogenetic and molecular genetic alterations associated with glioma formation and progression have been intensely studied and genetic profiles as additional aids to the definition of brain tumors have been incorporated in the WHO classification.
  • In fact, first steps have been undertaken in supplementing classical histopathological diagnosis by the use of molecular tests, such as MGMT promoter hypermethylation in glioblastomas or detection of losses of chromosome arms 1p and 19q in oligodendroglial tumors.
  • The tremendous progress that has been made in the use of array-based profiling techniques will likely contribute to a further molecular refinement of glioma classification and lead to the identification of glioma core pathways that can be specifically targeted by more individualized glioma therapies.
  • [MeSH-major] Biomarkers, Tumor. Brain Neoplasms / metabolism. Glioma / metabolism
  • [MeSH-minor] Animals. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Gene Expression Profiling. Humans. Molecular Diagnostic Techniques. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):129-36 [17031656.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):583-93 [16909125.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):133-43 [11303789.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):185-9 [11307615.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):359-67 [11438483.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):808-16 [11487055.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Acta Neuropathol. 2001 Jul;102(1):69-74 [11547953.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Dec;60(12):1170-80 [11764089.001]
  • [Cites] Acta Neuropathol. 2002 Feb;103(2):152-6 [11810181.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):370-5 [11920588.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):929-39 [11953826.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] Acta Neuropathol. 2002 Aug;104(2):206-8 [12111364.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):416-27 [12112531.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9 [12484572.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):752-7 [12640683.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):134-42 [12850376.001]
  • [Cites] Mol Carcinog. 1993;8(2):74-80 [8397797.001]
  • [Cites] Oncogene. 1994 Mar;9(3):949-54 [8108140.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4299-303 [8044775.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6321-4 [7987821.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Neurogenetics. 2001 Jul;3(3):159-62 [11523567.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):853-7 [9284834.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):84 [9973931.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):123-9 [10068201.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2080-6 [18709645.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42 [15624760.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2368-76 [17285580.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Brain Pathol. 2007 Jan;17(1):5-10 [17493032.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6091-6 [10626796.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Dec;67(12):1194-204 [19018242.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):193-9 [15799819.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2565-71 [15805250.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):75-81 [16051033.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):322-6 [16049942.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):95-103 [15880582.001]
  • [Cites] Mol Cancer. 2005;4:35 [16156899.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1693-9 [16116609.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5010-6 [17311001.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2503-10 [18302158.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Sep;62(9):927-35 [14533782.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 [14575240.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7600-5 [14633674.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Dec;29(6):574-83 [14636164.001]
  • [Cites] Acta Neuropathol. 2004 Mar;107(3):277-82 [14730454.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):182-3 [15172758.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Neuropathol Exp Neurol. 1974 Jul;33(3):456-71 [4365915.001]
  • [Cites] Clin Neuropathol. 1982;1(4):139-50 [6188569.001]
  • [Cites] J Neuropathol Exp Neurol. 1988 Mar;47(2):101-18 [3339369.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1759-65 [16541434.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Cancer Biol Ther. 2006 Mar;5(3):300-4 [16410724.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5618-23 [16740698.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • (PMID = 19333441.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2662467
  • [Keywords] NOTNLM ; 19q / 1p / Glioblastoma / MGMT / biomarker / ependymoma / genetics / molecular diagnostics / oligodendroglioma / profiling
  • [General-notes] NLM/ Original DateCompleted: 20100621
  •  go-up   go-down


56. Keller A, Comtesse N, Ludwig N, Meese E, Lenhof HP: SePaCS--a web-based application for classification of seroreactivity profiles. Nucleic Acids Res; 2007 Jul;35(Web Server issue):W683-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sophisticated statistical learning approaches are trained on the resulting data set to classify sera as either tumor or normal sera.
  • We demonstrate the functionality of SePaCS exemplarily for meningioma, a generally benign intracranial tumor.
  • As a second example, we evaluated SePaCS on glioma, a malignant brain tumor.
  • SePaCS is freely available at http://www.bioinf.uni-sb.de/sepacs.
  • [MeSH-major] Blood Proteins / chemistry. Brain Neoplasms / blood. Computational Biology / methods. Gene Expression Regulation, Neoplastic. Genetic Markers. Glioma / blood. Internet. Meningioma / blood

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1792-8 [16452240.001]
  • [Cites] BMC Bioinformatics. 2006;7:539 [17184519.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1224-35 [16177248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6 [15983380.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3034-44 [15226172.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Urol. 2005 May;173(5):1456-62 [15821460.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • (PMID = 17478503.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Genetic Markers; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1933220
  •  go-up   go-down


57. Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother; 2009 Apr;9(4):535-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder characterized by numerous cutaneous features, including café-au-lait macules, skinfold freckling and iris hamartomas.
  • In addition, individuals with NF1 are prone to the development of both benign and malignant tumors.
  • The most common CNS tumor in children and adults with NF1 is the glioma.
  • Adults, in contrast, are more likely to develop higher grade gliomas, which are treated in a similar fashion as their sporadic counterparts.
  • [MeSH-major] Brain Neoplasms / complications. Glioma / complications. Neurofibromatosis 1 / complications


58. Blomquist E, Bjelkengren G, Glimelius B: The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol; 2005;44(8):862-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In intracranial benign and malignant tumours, it is estimated that between 130 and 180 patients each year are candidates for proton beam therapy.
  • Of these, between 50 and 75 patients have malignant glioma, 30-40 meningeoma, 20-25 arteriovenous malformations, 20-25 skull base tumours and 10-15 pituitary adenoma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Eye Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Dosage
  • [MeSH-minor] Adenoma / radiotherapy. Chordoma / radiotherapy. Glioma / radiotherapy. Humans. Meningeal Neoplasms / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Skull Neoplasms / radiotherapy. Sweden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332593.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protons
  • [Number-of-references] 93
  •  go-up   go-down


59. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci; 2006 Dec;256(8):516-21
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003.
  • OBJECTIVES: To assess the long-term survival of brain tumor patients, and in particular to evaluate the relation of quality of life (QOL) to survival among low-grade glioma patients.
  • METHODS: The postoperative survival of 101 brain tumor patients was followed from surgery (1990-1992) until the end of the year 2003.
  • RESULTS: The mean survival times in years (SD) were significantly related to tumor malignancy, being the shortest, 1.9 (0.6), for patients with high-grade gliomas, while patients with low-grade gliomas or a benign brain tumor had mean survival times of 9.1 (1.0) and 11.6 (0.5), respectively.
  • At all follow-ups, depressed low-grade glioma patients had a significantly shorter survival time, 3.3-5.8 years, compared to non-depressed low-grade glioma patients, 10.0-11.7 years.
  • A decreased level of QOL in low-grade glioma patients was significantly related to the shorter survival.
  • CONCLUSIONS: The results suggest that depression and decreased QOL among low-grade glioma patients is related to shorter survival at long-term follow-up.
  • Decreased QOL may serve as an indicator for poor prognosis in low-grade glioma patients.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / psychology. Depressive Disorder / mortality. Depressive Disorder / psychology. Glioma / mortality. Glioma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / mortality. Postoperative Complications / psychology. Prognosis. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16960653.001).
  • [ISSN] 0940-1334
  • [Journal-full-title] European archives of psychiatry and clinical neuroscience
  • [ISO-abbreviation] Eur Arch Psychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


60. Matsumura A, Isobe T, Anno I, Takano S, Kawamura H: Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study. J Clin Neurosci; 2005 May;12(4):416-20
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: There were seven benign and seven malignant gliomas.
  • RESULT: A positive correlation was observed between Cho and MIB-1 in benign gliomas, whereas there was a trend to an inverse correlation in malignant gliomas.
  • This inverse correlation became a positive correlation when the necrotic area of the tumor (on the T1-weighted gadolinium enhanced images) was excluded from the voxel of interest (VOI) for MRS, but this correlation did not reach statistical significance.
  • CONCLUSIONS: The quantification data clarified the behavior of Cho in malignant gliomas.
  • In particular, the levels of other commonly measured metabolites, including Cre, may also be altered in glioma, making ratios between metabolites misleading.
  • Heterogeneity in the MRS VOI should be considered when evaluating the proliferative activity of malignant glioma by MRS.
  • [MeSH-major] Brain Neoplasms / metabolism. Choline / metabolism. Glioma / metabolism. Ki-67 Antigen / metabolism. Magnetic Resonance Spectroscopy / methods. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925772.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


61. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M: In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small; 2008 Mar;4(3):372-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Converging advances in the development of nanoparticle-based imaging probes and improved understanding of the molecular biology of brain tumors offer the potential to provide physicians with new tools for the diagnosis and treatment of these deadly diseases.
  • Here a biocompatible nanoprobe composed of a poly(ethylene glycol) (PEG) coated iron oxide nanoparticle that is capable of specifically targeting glioma tumors via the surface-bound targeting peptide, chlorotoxin (CTX), is presented.
  • High targeting specificity and benign biological response establish this nanoprobe as a potential platform to aid in the diagnosis and treatment of gliomas and other tumors of neuroectodermal origin.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6882-8 [17638899.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):13-24 [17520692.001]
  • [Cites] Nat Med. 2007 Mar;13(3):372-7 [17322898.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Mar;4(2):175-86 [17335414.001]
  • [Cites] Cell Mol Life Sci. 2007 Feb;64(4):458-78 [17260089.001]
  • [Cites] J Biomed Mater Res A. 2006 Sep 1;78(3):550-7 [16736484.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] Drug Discov Today. 2005 Nov 1;10(21):1451-8 [16243265.001]
  • [Cites] J Am Chem Soc. 2005 Sep 7;127(35):12387-91 [16131220.001]
  • [Cites] Nano Lett. 2005 Jun;5(6):1003-8 [15943433.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] J Magn Reson Imaging. 1999 Feb;9(2):228-32 [10077018.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Exp Neurol. 1997 Jan;143(1):61-9 [9000446.001]
  • [Cites] Radiology. 1995 Nov;197(2):533-8 [7480707.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2727-31 [7743477.001]
  • [Cites] J Neurosurg. 1990 Sep;73(3):331-44 [2166779.001]
  • [Cites] J Neurol. 1981;224(3):183-92 [6162014.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Oct;30(5):456-71 [15488022.001]
  • [Cites] Biomed Microdevices. 2004 Mar;6(1):33-40 [15307442.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):370-5 [15265744.001]
  • [Cites] J Am Chem Soc. 2004 Jun 16;126(23):7206-11 [15186157.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Glia. 2002 Aug;39(2):162-73 [12112367.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Apr;23(4):510-9 [11950637.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Bioconjug Chem. 2000 Nov-Dec;11(6):941-6 [11087345.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):283-318 [11356986.001]
  • [Cites] Adv Enzyme Regul. 2001;41:189-207 [11384745.001]
  • [Cites] Eur Radiol. 2001;11(11):2319-31 [11702180.001]
  • [Cites] Biomaterials. 2002 Apr;23(7):1553-61 [11922461.001]
  • (PMID = 18232053.001).
  • [ISSN] 1613-6829
  • [Journal-full-title] Small (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Small
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA119408-04; United States / NCI NIH HHS / CA / R01CA119408; United States / NCI NIH HHS / CO / N01CO37122; United States / NCI NIH HHS / CA / N01CO37122; United States / NCI NIH HHS / CA / R01 CA119408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Chlorotoxin; 0 / Scorpion Venoms; 30IQX730WE / Polyethylene Glycols
  • [Other-IDs] NLM/ NIHMS109521; NLM/ PMC2692358
  •  go-up   go-down


62. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • Understanding the mechanisms involved in glioma invasion could lead to new therapeutic strategies.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • B/b(sia) is an oversialylated isoform expressed by about half the high- and low-grade gliomas analyzed.
  • B/b(Deltag) lacks most of the carbohydrates typically present on BEHAB/brevican and is the major up-regulated isoform of this protein in high-grade gliomas but is absent in a specific subset of low-grade, indolent oligodendrogliomas.
  • The glioma-specific expression of B/b(Deltag), its restricted membrane localization, and its expression in all high-grade gliomas tested to date suggest that it may play a significant role in glioma progression and make it an important new potential therapeutic target.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


63. Figarella-Branger D, Colin C, Chinot O, Nanni I, Baeza N, Fina F, Tong S, Eudes N, Quilichini B, Romain S, Metellus P, Fuentes S, Barrié M, Boucard C, Fraslon C, Bonavita MJ, Martin PM, Ouafik L: [AP-HM tumour tissue bank: molecular signature of gliomas]. Med Sci (Paris); 2006 Jan;22 Spec No 1:54-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumorothèque de l'AP-HM: cartographie moléculaire des gliomes.
  • The AP-HM tissue bank is the largest one in France regarding some collections, including brain tumors.
  • In particular because some benign gliomas such as pilocytic astrocytomas (WHO grade I) can be misclassified as malignant ones such as glioblastomas (grade IV) the first aim of our study was to find accurate diagnostic markers.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Tissue Banks

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705945.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


64. Shah NC, Ray A, Bartels U, Rutka J, Bouffet E, Drake J, Hawkins CE, Huang A: Diffuse intrinsic brainstem tumors in neonates. Report of two cases. J Neurosurg Pediatr; 2008 May;1(5):382-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intrinsic pontine tumors, characteristically seen in school-age children, are most often high-grade gliomas that are almost invariably fatal.
  • In one child, postmortem examination revealed a primary brainstem primitive neuroectodermal tumor.
  • The authors conclude that, as in older children, neonatal intrinsic brainstem tumors may be of a highly malignant nature.
  • The rapid tumor progression in both cases indicates that where a diagnostic procedure may pose significant risks, supportive observation can aid in distinguishing malignant from benign tumor growth.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy. Glioma / pathology. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Pediatr. 2008 May;1(5):381; discussion 381 [18447672.001]
  • (PMID = 18447673.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA: Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood; 2008 Jan 15;111(2):800-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we show that the transcription factor Sox11 is specifically expressed in the nucleus of MCL compared with other lymphomas and benign lymphoid tissue.
  • Sox11 mRNA is increased in gliomas compared with healthy brain tissue, suggesting a role in malignant transformation and/or cell survival.
  • Our novel finding of specific overexpression of Sox11 mRNA and nuclear protein in both cyclin D1-positive and - negative MCL may be useful for the diagnosis of MCL as a complement to cyclin D1 and also suggests a functional role for Sox11 in MCL.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Nucleus / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Leukemic. High Mobility Group Proteins / biosynthesis. Lymphoma, Mantle-Cell / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Antigens, CD20 / genetics. Antigens, CD20 / metabolism. Antigens, CD5 / genetics. Antigens, CD5 / metabolism. B-Lymphocytes / pathology. Brain / metabolism. Brain / pathology. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Central Nervous System / embryology. Central Nervous System / metabolism. Central Nervous System / pathology. Cyclin D. Cyclins / genetics. Cyclins / metabolism. Embryo, Mammalian / metabolism. Embryo, Mammalian / pathology. Gene Expression Profiling. Gene Expression Regulation, Developmental. Glioma / genetics. Glioma / metabolism. Glioma / pathology. Humans. Lymphopoiesis / genetics. Oligonucleotide Array Sequence Analysis. Organ Specificity. SOXC Transcription Factors. Sequence Homology, Amino Acid. Trans-Activators / biosynthesis. Trans-Activators / genetics


66. Teo C, Broggi M: Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams. Childs Nerv Syst; 2010 Sep;26(9):1219-25
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Despite the lack of evidence in literature, it is widely felt that patient outcomes will be improved by adopting a multidisciplinary team (MDT) approach to children with brain tumors.
  • METHODS: A retrospective study was conducted on all pediatric brain and spinal cord tumor patients operated in a single center from 1999 to 2009.
  • Details of preoperative treatment, diagnosis and clinical status, postoperative diagnosis, early and late outcomes, progression-free survival and overall survival, and parental satisfaction were reviewed.
  • In ten cases, radical removal of the tumor resulted in a change in histological diagnosis, usually from a presumed diagnosis of malignancy to a more benign variety (n = 6).
  • [MeSH-major] Adenoma / surgery. Brain Neoplasms / surgery. Glioma / surgery. Salvage Therapy. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2010 Sep;26(9):1227-8 [20574741.001]
  • [ErratumIn] Childs Nerv Syst. 2010 Dec;26(12):1833. Charles, Teo [corrected to Teo, Charles]; Morgan, Broggi [corrected to Broggi, Morgan]
  • (PMID = 20563727.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M, Herms J, Koch W, Tatsch K, Tonn JC: Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery; 2005 Sep;57(3):505-11; discussion 505-11
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas.
  • OBJECTIVE: New treatment modalities are available for patients with glioma, which may lead to unspecific changes in posttherapeutic magnetic resonance imaging (MRI) findings.
  • Differentiation between tumor- and therapy-associated contrast enhancement on MRI scans after treatment may be difficult.
  • The aim of this study was to analyze the diagnostic value of O-(2-[F]fluoroethyl)-l-tyrosine (FET)-positron emission tomography (PET) and MRI in the detection of tumor recurrence in patients with glioma after radiotherapy, radiosurgery, or multimodal treatment.
  • METHODS: The study included 36 patients with gliomas and neuroradiological diagnosis of tumor recurrence and 9 patients who had undergone radioimmunotherapy.
  • A tissue diagnosis was made for comparative analysis in all patients with progressive neuroradiological or clinical findings (32 of 45 patients).
  • In patients with transient neuroradiological or clinical deterioration (13 of 45 patients), clinical follow-up was used to support or contradict the imaging-based diagnosis.
  • RESULTS: Tumor recurrence was documented in 31 of 45 patients, and 14 of 45 patients were tumor free.
  • FET-PET and MRI revealed a correct diagnosis in 44 and 36 patients, respectively.
  • Specificity of FET-PET was 92.9%, and sensitivity was 100% (in patients suspected of having recurrent tumor as revealed by MRI).
  • CONCLUSION: For patients with gliomas undergoing multimodal treatment or various forms of irradiation, conventional follow-up with MRI is insufficient to distinguish between benign side effects of therapy and tumor recurrence.
  • FET-PET is a powerful tool to improve the differential diagnosis in these patients.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Glioma / diagnosis. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Recurrence. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145529.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


68. Pearl PL: Neurological problems of jazz legends. J Child Neurol; 2009 Aug;24(8):1037-42
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • George Gershwin resisted explanations for uncinate seizures and personality change and herniated from a right temporal lobe brain tumor, which was a benign cystic glioma.

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666887.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Cavaliere R, Lopes MB, Schiff D: Low-grade gliomas: an update on pathology and therapy. Lancet Neurol; 2005 Nov;4(11):760-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gliomas: an update on pathology and therapy.
  • Low-grade gliomas (LGG) are not benign neoplasms.
  • Although the survival of patients with LGG is better than that of patients with higher-grade tumours, many of the treatments can produce or contribute to chronic impairment, particularly radiotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioma / pathology. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239183.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


70. Robert M, Wastie M: Glioblastoma multiforme: a rare manifestation of extensive liver and bone metastases. Biomed Imaging Interv J; 2008 Jan;4(1):e3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumours known collectively as gliomas.
  • As a rule, their behaviour can be predicted from histology: Grade I (pilocytic astrocytomas) and Grade II (benign astrocytomas) tumours are of low grade and grow slowly over many years.
  • Grade IV tumours (GBM) are the most aggressive and, unfortunately, also the most common in humans, growing rapidly, invading and altering brain function.
  • These tumours arise from the supporting glial cells of the brain during childhood and in adulthood.These growths do not spread throughout the body like other forms of cancer, but cause symptoms by invading the brain.
  • Most patients with GBM die of their disease in less than a year and none have long term survival.Extracranial metastases from GBM are extremely rare, with a reported frequency of only 0.44% because of the absence of lymphatics in the brain and the difficulty of tumours to penetrate blood vessels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4833-6 [7585516.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2149-53 [1311985.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]
  • [Cites] Clin Imaging. 1994 Oct-Dec;18(4):386-9 [8000959.001]
  • (PMID = 21614314.001).
  • [ISSN] 1823-5530
  • [Journal-full-title] Biomedical imaging and intervention journal
  • [ISO-abbreviation] Biomed Imaging Interv J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3097703
  • [Keywords] NOTNLM ; GBM / Glioblastoma multiforme / extracranial metastases / glioma
  •  go-up   go-down


71. Tetzlaff MT, Liu P, O'Malley BW Jr, LiVolsi VA, Elder D: Report of a case of sinonasal undifferentiated carcinoma arising in a background of extensive nasal gliomatosis. Head Neck; 2008 Apr;30(4):549-55
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal glial heterotopia is a benign congenital condition in which mature benign brain tissue develops outside the central nervous system.
  • Imaging showed a radiologically malignant mass lesion.
  • In addition to SNUC, the resection specimen revealed extensive, multifocal nasal glial heterotopia (so called "nasal glioma").
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Chemotherapy, Adjuvant. Frontal Lobe / pathology. Humans. Male. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972313.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Skardelly M, Armbruster FP, Meixensberger J, Hilbig H: Expression of Zonulin, c-kit, and Glial Fibrillary Acidic Protein in Human Gliomas. Transl Oncol; 2009 Aug 18;2(3):117-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hallmarks of human malignant gliomas are their marked invasiveness and vascularity.
  • Because angiogenesis and tumor invasion have been associated with extracellular matrix degradation and intercellular tight junctions, the involvement of zonulin in glioma biology is in the focus.
  • The meningioma WHO I is regarded as benign, whereas the meningioma WHO III is recognized as the transition form of malignant tumors in humans.
  • Both are correlated to the degree of malignancy of human brain tumors.
  • The expression of zonulin is correlated to the degradation of the blood-brain barrier as revealed by Griffonia simplicifolia lectin.
  • In differently graded tumors, we found differently graded involvement of blood vessels in the tumor development, explaining patients' survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2006 Apr;41(4):408-19 [16635908.001]
  • [Cites] Clin Neuropathol. 2006 May-Jun;25(3):107-14 [16719406.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):163-7 [16132509.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):195-202 [16132504.001]
  • [Cites] J Clin Invest. 1989 Feb;83(2):724-7 [2492310.001]
  • [Cites] J Clin Invest. 1989 Apr;83(4):1089-94 [2649511.001]
  • [Cites] Infect Immun. 2003 Apr;71(4):1897-902 [12654806.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1607-15 [12404235.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:214-22 [11193578.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19160-5 [11278543.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 24:4435-40 [11082037.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Nov;24(6):687-91 [19122516.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • (PMID = 19701495.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730142
  •  go-up   go-down


73. Naydenov E, Tzekov C, Minkin K, Nachev S, Marinov M: [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature]. Khirurgiia (Sofiia); 2009;(2-3):69-74
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature].
  • INTRODUCTION: Ganglioglioma is an uncommon type of primary brain tumors.
  • In most of the cases the tumor demonstrates benign clinical behaviour with long-term patients' survival.
  • We present two cases ofhistologically confirmed anaplastic ganglioglioma in which malignant progression into a glioblastoma multiforme was seen.
  • The tumor was excised partially and the histological result was anaplastic ganglioglioma (World Health Organization - WHO. gr. III).
  • A local tumor recurrence was found and the patient underwent second operative intervention with gross total tumor resection.
  • IV glioma). The patient improved after the procedure.
  • An involvement of the contralateral cerebral hemisphere was found on control CT-scan ten months later.
  • The patient died after one month, 23 months after her initial diagnosis.
  • MRI data for large, heterointense tumor lesion in the left frontal lobe was found.
  • A subtotal tumor removal was made.
  • Data for additional local tumor growth was found on control CT-scan one month later.
  • 20 months after the initial diagnosis.
  • The tumor behaviour may vary between the patients in spite of the similar histological characteristics which indicates the possible presence of different tumor subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology


74. Gole B, Durán Alonso MB, Dolenc V, Lah T: Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res; 2009 Dec;15(4):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cells that migrate away from a central tumour into brain tissue are responsible for inefficient glioblastoma treatment.
  • Reportedly, the expression of cathepsins B, L and S gradually increases in the progression from benign astrocytoma to the malignant glioblastoma, although their specific roles in glioma progression have not been revealed.
  • Finally the study points out on the complexity of protease regulation and the need to include functional proteomics in the systems biology approaches to understand the processes associated with glioma invasion and progression.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cathepsin B / metabolism. Cell Movement / physiology. Glioblastoma / metabolism. Glioblastoma / pathology. Protein Biosynthesis / physiology
  • [MeSH-minor] Adult. Aged. Cathepsin L / metabolism. Cathepsins / metabolism. Cell Line, Tumor. Collagen / metabolism. Cystatins / metabolism. Drug Combinations. Female. Humans. Laminin / metabolism. Male. Middle Aged. Neoplasm Invasiveness / physiopathology. Proteoglycans / metabolism. Spheroids, Cellular / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434518.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cystatins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cathepsins; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.27 / cathepsin S
  •  go-up   go-down


75. Yonekawa Y: [On the occasion of my retirement as head of the Neurochirurgische Universitätsklinik Zürich--changing aspects of treatment modality in modern neurosurgery and of neuroscience research. Presentation of our experience and historical backgrounds]. Brain Nerve; 2008 May;60(5):538-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioma surgery especially glioblastoma surgery the most frequent surgery in our department around 170 / year contributed to improvement of both life expectancy and quality of life by development of therapy modalities (irradiation microsurgery and chemotherapy).
  • Acoustic neurinoma (just less than 20/year) is one of benign brain tumours whose treatment has changed remarkably.
  • [MeSH-minor] Brain Neoplasms / surgery. Cerebral Revascularization / methods. Cerebral Revascularization / trends. Humans. Hydrocephalus / surgery. Intracranial Aneurysm / surgery. Intracranial Arteriovenous Malformations / surgery. Switzerland. Universities

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516976.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 33
  •  go-up   go-down


76. Yu T, Zeng C, Zhao JZ: [Intracranial subependymoma: clinical features and surgical management of 22 cases]. Zhonghua Yi Xue Za Zhi; 2010 Mar 23;90(11):756-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One tumor was located in temporal lobe, mesencephalon, thalamus and pons.
  • CONCLUSION: Intracranial subependymoma is a rare benign tumor.
  • The prognosis is excellent and there is a rare tumor recurrence.
  • [MeSH-major] Brain Neoplasms. Glioma, Subependymal

  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627021.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tectal plate is a rare location for a tumor.
  • In this paper we describe our experience in treating seven patients with tectal plate lesions, with different ages and types of pathology: five patients presented with low grade gliomas, one with lung cancer metastasis and the last presenting with a tectal plate cavernoma.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • When a patient presents with a benign lesions in the tectal region, treating the main symptom--hydrocephalus--should be the first attempt in management of these lesions.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


78. Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P, Figarella-Branger D: In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathol Appl Neurobiol; 2006 Apr;32(2):189-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All tumoral explants contain A2B5+ cells and can generate migrating cells with distinctive functional properties according to glioma subtypes.
  • Therefore, pilocytic astrocytomas contain slowly dividing oligodendrocyte-type2-astrocyte/oligodendrocyte precursor cells in keeping with their benign behaviour whereas both glioblastomas and oligodendrogliomas contain neoplastic glial restricted precursor cells.
  • [MeSH-major] Brain Neoplasms / physiopathology. Glioma / pathology. Neuroglia / cytology. Stem Cells / cytology


79. Nagesh V, Tsien CI, Chenevert TL, Ross BD, Lawrence TS, Junick L, Cao Y: Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1002-10
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study.
  • PURPOSE: To quantify the radiation-induced changes in normal-appearing white matter before, during, and after radiotherapy (RT) in cerebral tumor patients.
  • METHODS AND MATERIALS: Twenty-five patients with low-grade glioma, high-grade glioma, or benign tumor treated with RT were studied using diffusion tensor magnetic resonance imaging.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Aug;236(2):647-52 [16040920.001]
  • [Cites] J Head Trauma Rehabil. 2003 Jul-Aug;18(4):307-16 [16222127.001]
  • [Cites] Magn Reson Med. 2006 Feb;55(2):302-8 [16408263.001]
  • [Cites] J Neurosci Res. 2006 Feb 15;83(3):392-402 [16397901.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):884-90 [16484697.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] Eur J Neurol. 2007 May;14(5):540-7 [17437614.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):51-5 [10656372.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Radiat Res. 2000 Apr;153(4):357-70 [10798963.001]
  • [Cites] Magn Reson Med. 2000 Aug;44(2):259-68 [10918325.001]
  • [Cites] J Med Primatol. 2001 Apr;30(2):81-7 [11491408.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Oct;82(10):1461-71 [11588754.001]
  • [Cites] Radiology. 2001 Nov;221(2):349-58 [11687675.001]
  • [Cites] Radiother Oncol. 2002 Apr;63(1):107-20 [12065111.001]
  • [Cites] Neuroimage. 2002 Nov;17(3):1429-36 [12414282.001]
  • [Cites] Neuroimage. 2003 Nov;20(3):1714-22 [14642481.001]
  • [Cites] Acta Neuropathol. 1968 Nov 1;11(4):267-74 [5710040.001]
  • [Cites] Cancer. 1979 Oct;44(4):1256-72 [387205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1966-72 [6478431.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):635-40 [3731021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):319-30 [2841263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1371-81 [2461919.001]
  • [Cites] Br J Radiol. 1988 Nov;61(731):1043-52 [3208008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):37-42 [2298633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):689-96 [2004945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):1089-91; discussion 1093-4 [1639645.001]
  • [Cites] Radiother Oncol. 1993 Oct;29(1):60-8 [8295989.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2828-35 [7954244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Brain Res. 1995 Feb 6;671(1):141-8 [7728526.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan;12(1):45-62 [7502957.001]
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):893-906 [8946355.001]
  • [Cites] Magn Reson Med. 1998 Jun;39(6):928-34 [9621916.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] Brookhaven Symp Biol. 1961 Nov;14:176-99 [14010110.001]
  • [Cites] J Neurol Sci. 2005 Mar 15;229-230:195-200 [15760639.001]
  • [Cites] Neuroimage. 2005 May 15;26(1):132-40 [15862213.001]
  • (PMID = 18313524.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113699-02; United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA113699-02; United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / 3P01 CA59827; United States / NCI NIH HHS / CA / CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878-01A2; United States / NCI NIH HHS / CA / P02 CA85878; United States / NCI NIH HHS / CA / P01 CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / R21 CA11369901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42273; NLM/ PMC2376211
  •  go-up   go-down


80. Murakami M, Imahori Y, Kimura S, Tatsuzawa K, Ohwada K, Inoue Y, Sasajima H, Mineura K: Positron emission tomography elucidates transport system and tumor proliferation in meningiomas. Oncol Rep; 2005 Oct;14(4):853-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography elucidates transport system and tumor proliferation in meningiomas.
  • To test the in vivo transport system and tumor proliferation of meningiomas, in comparison with gliomas, 25 patients with meningiomas and 8 gliomas underwent quantitative kinetic analysis of ([18F])fluoro-2-deoxy-D-glucose (FDG) - positron emission tomography (PET) imaging and immunohistochemical study.
  • Surgical specimens were evaluated by means of three different methods: i) immunoreactivity to vascular endothelial growth factor (VEGF) and glucose transporter-1 (Glut-1), representing the permeability of tumor vessels;.
  • K1 was higher in meningiomas than in gliomas and was higher in atypical than in benign meningiomas. k3 was correlated with MIB-1 LI in meningiomas, but not in gliomas.
  • Immunohistochemically, meningiomas were less reactive to VEGF or Glut-1 than gliomas but atypical meningiomas stained more intensely than benign meningiomas.
  • The vascular surface area was significantly larger in meningiomas than in gliomas and atypical meningiomas had high values for both permeability and surface area than benign meningiomas.
  • High values for K1 and k3 indicate the aggressive proliferation of meningiomas and, in atypical meningiomas, the synergistic interaction of the high permeability and the large surface area yielded conditions conducive to glucose metabolism and tumor proliferation.
  • Evaluation of K1 and k3 facilitates to predict the tumor aggressiveness and to optimize the surgical management.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasms / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Biological Transport. Cell Proliferation. Female. Glioma / pathology. Glucose Transporter Type 1 / metabolism. Humans. Immunohistochemistry. Kinetics. Male. Middle Aged. Models, Statistical. Neoplasm Invasiveness. Permeability. Time Factors. Vascular Endothelial Growth Factor A / metabolism. von Willebrand Factor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142342.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor
  •  go-up   go-down


81. Paulino AC, Mai WY, Chintagumpala M, Taher A, Teh BS: Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys; 2008 Aug 1;71(5):1381-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced malignant gliomas: is there a role for reirradiation?
  • PURPOSE: To review the literature regarding the role of radiotherapy (RT) in the treatment of patients with radiation-induced malignant gliomas (RIMGs).
  • RESULTS: Initial tumor types treated with RT included brain tumor in 37 patients (40%), acute lymphoblastic leukemia in 33 (36%), benign disease in 11 (12%), and other in 11 (12%).
  • The RIMG occurred within 10 years after RT in 81% of patients with acute lymphoblastic leukemia/lymphoma, 59% of patients with brain/other, and 18% of patients with benign conditions (p = 0.002).
  • CONCLUSIONS: The RIMG appeared earlier in patients treated for leukemia and lymphoma and latest for those treated for a benign condition.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Neoplasms, Radiation-Induced / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):304-5; author reply 305 [18722290.001]
  • (PMID = 18262733.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


82. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M: Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci; 2009 Sep;100(9):1597-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFR is a key component of autonomous growth signaling in several tumors, and correlates with the malignancy grade of astrocytoma.
  • In this study, we tested the hypothesis that over-expression of ADAM17 in cortical astrocytes derived from normal brain would induce a progression towards a malignant phenotype.
  • When implanted in the nude mouse brain, CTX-TNA2 cells induced low histological grade, benign intraventricular gliomas.
  • In contrast, the same astrocytes with hADAM17 formed large malignant gliomas.
  • Taken together, these findings suggest that unregulated ADAM17 activity induces functional changes in astrocytes that significantly advance the malignant phenotype.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2007 Dec;85(16):3523-9 [17526018.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1287-98 [17907959.001]
  • [Cites] Growth Factors. 2007 Aug;25(4):253-63 [18092233.001]
  • [Cites] World J Gastroenterol. 2008 Apr 28;14(16):2487-93 [18442194.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7 [18427106.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2821-7 [18539960.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4829-42 [18490439.001]
  • [Cites] Cell Mol Life Sci. 2008 Jul;65(14):2232-43 [18535782.001]
  • [Cites] Biol Chem. 2008 Aug;389(8):1075-84 [18979631.001]
  • [Cites] PLoS One. 2008;3(11):e3769 [19020659.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1045-54 [19395875.001]
  • [Cites] Trends Genet. 2000 Feb;16(2):83-7 [10652535.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):1-12 [12003665.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3335-9 [12067969.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1114-24 [12606576.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1324-32 [12618757.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38829-39 [12832423.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):317-29 [14724562.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1943-50 [15026328.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5283-90 [15289334.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2735-9 [15309730.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1743-53 [15509542.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6467-71 [1378628.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):77-81 [8204695.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] EMBO J. 1997 Feb 17;16(4):750-9 [9049304.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):303-14 [9440027.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43 [15688065.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):349-56 [15925591.001]
  • [Cites] J Pathol. 2005 Oct;207(2):156-63 [16041691.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):867-74 [16424019.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8083-90 [16912185.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9045-53 [16982746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14825-30 [16990429.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):337-45 [17218988.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):417-27 [17367064.001]
  • [Cites] Adv Cancer Res. 2007;97:203-24 [17419947.001]
  • [Cites] Cancer Sci. 2007 May;98(5):674-84 [17355261.001]
  • [Cites] Biochem Cell Biol. 2007 Feb;85(1):141-9 [17464354.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):30-41 [17321672.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 28;361(3):586-92 [17673180.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • (PMID = 19515085.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043892-17; United States / NCI NIH HHS / CA / R01 CA100486-04; United States / NCI NIH HHS / CA / P01 CA043892; United States / NCI NIH HHS / CA / CA100486-04; United States / NCI NIH HHS / CA / R01 CA100486; United States / NCI NIH HHS / CA / P01 CA043892-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  • [Other-IDs] NLM/ NIHMS142282; NLM/ PMC2756136
  •  go-up   go-down


83. Mehrotra N, Shamji MF, Vassilyadi M, Ventureyra EC: Intracranial tumors in first year of life: the CHEO experience. Childs Nerv Syst; 2009 Dec;25(12):1563-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: One seventh of pediatric brain tumors are diagnosed in the first year of life.
  • METHODS: A retrospective review was performed of brain tumor patients presenting to the Children's Hospital of Eastern Ontario (CHEO) through the last 34 years.
  • RESULTS: Eighteen cases of brain tumors in the first year of life were identified: 12 suptratentorial, eight with benign histology, and six infratentorial all with malignant histology.
  • CONCLUSIONS: Brain tumors in the first year of life represent 4.8% of patients treated at CHEO.
  • Mode of presentation, utilization of adjuvant therapy, and survival depend on tumor location and histology, with worse prognosis for infratentorial lesions.
  • [MeSH-major] Glioma / therapy. Infratentorial Neoplasms / therapy. Meningioma / therapy. Neuroectodermal Tumors, Primitive / therapy. Supratentorial Neoplasms / therapy. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551387.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Ternier J, Wray A, Puget S, Bodaert N, Zerah M, Sainte-Rose C: Tectal plate lesions in children. J Neurosurg; 2006 Jun;104(6 Suppl):369-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, 80% of the surgically treated lesions were low grade (with the other 20% consisting of one dysplasia, one high-grade tumor, and one unidentified tumor).
  • One patient died of a high-grade astrocytoma after undergoing surgery and radiotherapy; the other 39 patients remain clinically stable.
  • The only factor predictive of tumor enlargement was lesion volume at presentation (p = 0.002).
  • Lesions with a volume less than 4 cm3 were likely to be hamartomas and followed a predominantly benign course, with few atypical cases progressing.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Glioma / pathology. Glioma / surgery. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776370.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Rosenfeld A, Listernick R, Charrow J, Goldman S: Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst; 2010 May;26(5):663-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1 and high-grade tumors of the central nervous system.
  • PURPOSE: Neurofibromatosis type 1 (NF1), a common genetic disorder, predisposes patients to the development of both benign and malignant tumors.
  • Although the most common central nervous system (CNS) tumor is a low-grade pilocytic astrocytoma of the optic pathway, there have been sporadic reports of NF1 patients with more aggressive CNS lesions.
  • METHODS: We conducted a retrospective review of all patients with NF1 and any CNS tumor being followed in the Children's Memorial Hospital NF1 Clinic.
  • RESULTS: Seven hundred forty patients with a diagnosis of NF1 were identified.
  • Five patients (3%) were identified as having high-grade tumors, which consisted of anaplastic medulloblastoma (n = 1) and high-grade glioma (n = 4).
  • The mean age at diagnosis of NF1 was 2 years.
  • Three of the five patients had a history of an OPT prior to the development of their high-grade lesions.
  • Currently, two patients are alive and receiving therapy at a mean of 10 months following diagnosis.
  • CONCLUSION: High-grade CNS tumors may occur in children with NF1.
  • Although tumors in NF patients are generally benign, clinicians should have a high index of suspicion of malignancy in patients whose tumors are in an unusual location or behave in an uncharacteristically aggressive manner.
  • [MeSH-major] Brain Neoplasms / complications. Neurofibromatosis 1 / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937438.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Qaddoumi I, Sultan I, Broniscer A: Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther; 2009 Jan;8(1):4-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric low-grade gliomas and the need for new options for therapy: Why and how?
  • Pediatric low-grade gliomas are the most common tumors of the central nervous system in children, accounting for almost 50% of all childhood brain tumors.
  • Most treatment studies address low-grade gliomas as a single entity, depriving us of histology-specific treatment outcomes.
  • This is mostly due to a lack of understanding of tumor biology at the molecular level.
  • Pediatric low-grade gliomas are not benign, and most incompletely resected tumors will progress and negatively affect quality of life.
  • Such progress in pilocytic astrocytoma needs to be consolidated and expanded to other histologic varieties of pediatric low-grade gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1993;86(1):81-5 [8103960.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):165-72 [7536455.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] Acta Neuropathol. 1995;90(3):319-22 [8525807.001]
  • [Cites] J Pediatr. 1995 Nov;127(5):718-22 [7472822.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):550-5 [9403205.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]
  • [Cites] J Neurosurg. 1999 Apr;90(2 Suppl):231-3 [10199253.001]
  • [Cites] Eur J Hum Genet. 1999 Apr;7(3):267-73 [10234502.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):556-60 [16150126.001]
  • [Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]
  • [Cites] J Neurosurg. 2005 Oct;103(4 Suppl):357-61 [16270688.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):301-7 [16195800.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):229-34 [11423771.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1350-5 [12507133.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):188-96 [12816725.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]
  • [Cites] Neuropathology. 2006 Oct;26(5):442-6 [17080723.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):895-903 [17503347.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1191-8 [14566704.001]
  • [Cites] Br J Neurosurg. 2003 Aug;17(4):327-35 [14579898.001]
  • [Cites] Neurol Res. 2003 Oct;25(7):691-3 [14579783.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):377-80 [15800886.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):136-42 [16611406.001]
  • [Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] J Neurosurg. 2006 May;104(5 Suppl):314-20 [16848088.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):430-7 [17704361.001]
  • [Cites] Br J Ophthalmol. 2008 Jan;92(1):40-6 [17962395.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):116-32 [17913600.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):892-9 [18098210.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1520-8 [18316617.001]
  • [Cites] Methods Enzymol. 2008;438:307-20 [18413257.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):121-34 [18473997.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):333-6 [18552517.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] PLoS One. 2008;3(8):e3065 [18725974.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] J Clin Oncol. 2012 Apr 20;30(12):1358-63 [22393086.001]
  • [Cites] Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):241-6 [18221149.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • [Cites] Clin Neuropathol. 2000 Mar-Apr;19(2):57-62 [10749285.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]
  • [Cites] Int J Hematol. 2003 Dec;78(5):383-9 [14704030.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):862-6 [4056900.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8323-7 [2682646.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):45-52 [2104571.001]
  • [Cites] Cell. 1990 Aug 10;62(3):599-608 [2116237.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Pediatr Neurosurg. 1992;18(4):207-17 [1472434.001]
  • (PMID = 19164945.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 97
  • [Other-IDs] NLM/ NIHMS161402; NLM/ PMC2810626
  •  go-up   go-down


87. Yoshida D, Kogiku M, Noha M, Takahashi H, Teramoto A: A case of pleomorphic xanthoastrocytoma presenting with massive tumoral hemorrhage. J Neurooncol; 2005 Jan;71(2):169-71
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma has been generally conceived to be in a benign nature, showing a relatively favorable prognosis.
  • Apoplectic attack attributable by massive hemorrhage in this distinct form of the supratentorial glioma is an exceedingly rare event.
  • CT and MRI disclosed the presence of a tumor composing of massive intra-tumoral hemorrhage filling the cyst associated with mural nodule in the left frontotemporal lobe.
  • The unusual hemorrhagic presentation of this typically benign entity is extremely rare and is thought to be intra-tumoral bleeding in this case, since subarachnoid hemorrhage was absent.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / complications. Brain Neoplasms / blood supply. Brain Neoplasms / complications. Cerebral Hemorrhage / etiology. Hematoma / etiology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2006 Mar;77(1):105-6 [16292492.001]
  • (PMID = 15690134.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Lemaire JJ, Khalil T, Bard JJ, Verrelle P: [Oligodendrogliomas and radiosurgery]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):393-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Place de la radiochirurgie dans le traitement des oligodendrogliomes.
  • Nevertheless, empirically, and in light of the limited constraints for the patient and the encouraging radiological and clinical benefits, radiosurgical teams usually propose this technique in the event of recurrence of malignant gliomas, as a second line treatment.
  • Exceptionally radiation can be used for some small benign gliomas which could not be treated by open surgery and accurately defined radiologically.
  • One of the key problems is the definition of the glioma boundaries.
  • Despite progress in neuroimaging techniques most the limits of malignant forms are still not accessible.
  • [MeSH-major] Brain Neoplasms / surgery. Oligodendroglioma / surgery. Radiosurgery / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292181.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 36
  •  go-up   go-down


89. Laxton AW, Shannon P, Nag S, Farb RI, Bernstein M: Rapid expansion of a previously asymptomatic subependymoma. Case report. J Neurosurg; 2005 Dec;103(6):1084-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One month after his initial presentation, he was admitted to the hospital with significant tumor expansion and clinical deterioration.
  • Histopathological analysis of this tumor showed central necrosis with associated edema in an otherwise typical and benign-appearing subependymoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Brain Edema / etiology. Cranial Fossa, Posterior. Craniotomy. Disease Progression. Headache / etiology. Humans. Male. Necrosis. Time Factors

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381197.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma (PA) is a slow-growing, well-circumscribed grade I glioma generally considered benign, with a low recurrence rate and an excellent prognosis following complete surgical resection.
  • PA is the most common central nervous system glioma in the pediatric population and is rare in adults.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • PA patients with subtotal resection may benefit from continued follow-up for up to 20 years after the initial diagnosis and resection.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • Pilocytic astrocytoma is a slow-growing, circumscribed glioma that most frequently occurs within the pediatric population.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • A high rate of malignant transformation was observed in the patients that underwent repeat surgery with 75% (3/4) progressing to anaplastic astrocytoma on pathological examination.
  • This study provides further evidence that the clinical course of a subset of adult patients with pilocytic astrocytoma will not be benign.
  • The potential for rapid tumor recurrence and malignant transformation necessitates careful post-operative follow-up for adult patients with this tumor.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Martin-Duverneuil N, Guillevin R, Chiras J: [Imaging of gliomas]. Cancer Radiother; 2008 Nov;12(6-7):669-75
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When associated, they allow also and perhaps especially to precise the diagnostic, particularly with other tumoral masses such as lymphomas or metastases that can present misleading patterns, but also with other more benign lesions such as abcesses.
  • Always critically analysed, and reevaluated along the time if necessary, they can sometimes help the histological diagnosis, but never can be used in place of it.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Brain Abscess / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Neovascularization, Pathologic. Oligodendroglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922727.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH: Central nervous system tumors. Mayo Clin Proc; 2007 Oct;82(10):1271-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although more than half of these tumors are benign, they can cause substantial morbidity.
  • Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years.
  • Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis.
  • Treatment depends on the histologic diagnosis.
  • Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence.
  • Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy.
  • Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control.
  • This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Glioma / diagnosis. Glioma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908533.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


94. Yao Z, Wang Y, Zee C, Feng X, Sun H: Computed tomography and magnetic resonance appearance of sporadic meningioangiomatosis correlated with pathological findings. J Comput Assist Tomogr; 2009 Sep-Oct;33(5):799-804

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Meningioangiomatosis (MA) is a rare benign localized lesion of leptomeninges and underlying cerebral cortex.
  • Preoperative diagnosis is difficult and challenging because of its diverse clinical, pathological, and imaging features.
  • [MeSH-major] Angiomatosis / diagnosis. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / diagnosis. Meningioma / blood supply. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Arteriovenous Malformations / diagnosis. Brain Neoplasms / diagnosis. Calcinosis / diagnosis. Calcinosis / pathology. Child. Contrast Media. Diagnosis, Differential. Diagnostic Errors. Female. Glioma / diagnosis. Humans. Image Enhancement / methods. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820515.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


95. Steiger HJ: Preventive neurosurgery: population-wide check-up examinations and correction of asymptomatic pathologies of the nervous system. Acta Neurochir (Wien); 2006 Oct;148(10):1075-83; discussion 1083
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early identification and correction of anomalies harbouring the risk of a catastrophic event such as aneurysms is the principal rationale for brain check-up programmes.
  • RATIONALE FOR CHECK-UP IMAGING AND PREVENTIVE TREATMENT: The average prevalence of asymptomatic intracranial benign tumours, aneurysms and carotid stenoses must be estimated as approximately 1% each.
  • The case of glioma appears to be lost since asymptomatic gliomas are extremely rarely identified on screening examinations, and on the other hand current treatment series do not support that infiltrating gliomas can be cured if only treated early enough.
  • Treatment of the benign tumours, hydrocephalus and arachnoid cysts in the asymptomatic stage does not appear to provide any benefit.
  • Brain-check-up programmes cannot be considered in isolation.
  • CONCLUSIONS: Population-wide screening with regard to intracranial aneurysms or carotid stenosis with non-invasive imaging techniques and preventive surgery/endovascular therapy can be justified, provided that treatment-associated morbidity is very low.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Diseases / prevention & control. Mass Screening / adverse effects. Neurosurgical Procedures / adverse effects


96. Schramm J, Aliashkevich AF: Surgery for temporal mediobasal tumors: experience based on a series of 235 patients. Neurosurgery; 2007 Feb;60(2):285-94; discussion 294-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the clinical characteristics, diagnosis, various approaches, and outcomes in a retrospective review of a large series of temporomediobasal (TMB) tumors.
  • METHODS: Charts from 235 patients with TMB tumors were identified from the glioma and epilepsy surgery database and from the electronic operations log.
  • The largest tumor groups were astrocytomas (38.0%), gangliogliomas (29.8%), dysembryoplastic neuroepithelial tumor (11.1%), and glioblastomas (11.1%).
  • The most frequent tumor location was the mesial Type A tumor (45.1%), with this type also showing the highest proportion of benign (World Health Organization Grades I and II) histological features (91.3%).
  • Of all tumors, 76.2% were benign.
  • Larger tumor size was associated with higher frequency of malignant histopathological findings.
  • Thirty-eight patients with low-grade tumors had undergone surgery previously.
  • CONCLUSION: Small tumor size, magnetic resonance imaging, and microsurgery have made resection of mostly benign TMB tumors possible in a large number of patients.
  • [MeSH-major] Brain Neoplasms / surgery. Neurosurgical Procedures. Temporal Lobe / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Neurosurgery. 2008 Jun;62(6 Suppl 3):1272-82 [18695547.001]
  • (PMID = 17290179.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Chittiboina P, Zhang S, Bao J, Vannemreddy P, Guthikonda B: Subependymoma at the foramen of Monro presenting with intermittent hydrocephalus: case report and review of the literature. J La State Med Soc; 2010 Jul-Aug;162(4):214-7
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymomas are benign neoplasms, accounting for 0.5 % of all central nervous system tumors.
  • However, patients may be symptomatic with the symptoms depending on location of the tumor.
  • The patient's tumor was asymptomatic for many years.
  • Even though our patient presented with a histologically benign ventricular tumor, she demonstrated rapidly worsening symptoms that culminated in herniation.
  • Once diagnosed, we recommend early tumor removal and restoration of normal cerebrospinal fluid (CSF) pathways for these intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Ventricles. Glioma, Subependymal / diagnosis. Hydrocephalus / etiology

  • Genetic Alliance. consumer health - Hydrocephalus.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882814.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kim JY, Kim HS, Lee S, Park JH: The expression of GLTSCR2, a candidate tumor suppressor, is reduced in seborrheic keratosis compared to normal skin. Pathol Res Pract; 2010 May 15;206(5):295-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of GLTSCR2, a candidate tumor suppressor, is reduced in seborrheic keratosis compared to normal skin.
  • Glioma tumor-suppressor candidate region gene 2 (GLTSCR2) is a recently identified nuclear protein that interacts with the tumor suppressor PTEN.
  • GLTSCR2 regulates the stability of PTEN, and is therefore believed to have a tumor suppressive function.
  • However, GLTSCR2 expression levels in human tumors and its mechanism of tumor suppression remain largely unknown.
  • We performed an immunohistochemical examination of GLTSCR2 expression in samples of seborrheic keratosis (SK, n=69), a common benign skin tumor, and normal skin (n=23), and assessed the relationship between GLTSCR2 expression and the patients' clinicopathologic factors.
  • Using in situ hybridization analysis, we found that mRNA expression of GLTSCR2 was reduced in tumor cells compared to normal skin.
  • This is the first study analyzing the expression of GLTSCR2, a putative tumor suppressor, in SK and normal skin.
  • [MeSH-major] Keratosis, Seborrheic / metabolism. Skin / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20185249.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / GLTSCR2 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


99. Adamson DC, Rasheed BA, McLendon RE, Bigner DD: Central nervous system. Cancer Biomark; 2010;9(1-6):193-210
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS).
  • The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor.
  • In adults, about half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are malignant.
  • For most benign CNS tumors that require treatment, neurosurgeons can offer curative resections or at least provide significant relief from mass effect.
  • Unfortunately, we still lack effective treatments for most primary and secondary malignant CNS tumors.
  • However, the past decade has witnessed an explosion in the understanding of the early molecular events in malignant primary CNS tumors, and for the first time in history, oncologists are seeing that a plethora of new therapies targeting these molecular events are being tested in clinical trials.
  • The vast majority of these are meningiomas, of which over 90% are benign.
  • Other much less common sites of primary CNS tumors include the pineal region, ventricular system, cerebellum, brain stem, cranial nerves, and spinal cord.
  • The distribution of CNS tumors by histology has seen a slight increase in more malignant tumors over the past decade, possibly due to increased neuroimaging practices or environmental exposures.
  • The benign meningiomas make up 32% of primary CNS tumors, followed by nerve sheath tumors and pituitary tumors.
  • Grade IV, the most malignant grade of astrocytoma, includes glioblastoma multiforme (GBM), the most common malignant primary CNS glioma in adults, which represents 51% of all CNS gliomas.
  • Here we describe the molecular and cellular events associated with malignant glioma initiation and progression.
  • We also review the importance of glioma stem cell biology and tumor immunology in early gliomagenesis.
  • In addition, we present a brief description of the most common malignant primary CNS glioma in pediatric patients - medulloblastoma, as well as familial cancer syndromes that include gliomas as part of the syndrome.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22112477.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Wang FL, Li XH, Gui QP, Liu L: [Clinicopathologic and radiologic features of dysembryoplastic neuroepithelial tumors]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):566-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features and radiologic findings of dysembryoplastic neuroepithelial tumor (DNT).
  • All tumors were located in the supratentorial cerebral cortex.
  • Simple variant was composed mainly of the glioneuronal element, accompanied by surrounding oligodendrocyte-like cells, and the complex variant contained a low-grade glioma component, in addition to the glioneuronal element and sometimes foci of cortical dysplasia.
  • CONCLUSIONS: DNT is a benign tumor with excellent prognosis after surgical excision.
  • Complex variant of DNT needs to be distinguished from other types of low-grade glioma.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Cortex / pathology. Neuroectodermal Tumors, Primitive / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468306.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Synaptophysin
  •  go-up   go-down






Advertisement